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Abstract
Abstract
In order to ensure a productive life cycle, Human Papillomaviruses (HPVs) require fine 
regulation of their gene products. Uncontrolled activity of the viral oncoproteins, E6 
and E7, results in the immortalisation of the infected epithelial cells and thus prevents 
the production of mature virions. Here, we investigate the regulation of HPV-16 E7 
activities through its interaction with both viral and cellular gene products. First, we 
show that HPV-16 E7 and E2 can interact directly and the region mediating this 
interaction is defined on each protein. The expression of E2 inhibits some of E7 
oncogenic activities including primary cell transformation, induction of centrosome 
abnormalities and pRB degradation. In addition, E2 can stabilise E7 and redirect its 
localisation where it can associate with some of E2’s activities such as transcriptional 
activation and mitotic chromosome binding. Secondly, we provide evidence that E7 
can be phosphorylated by CDK2 in vitro preferentially on its N-terminal domain, and 
we hypothesise that this occurs on more than one residue on E7. In vivo, we show that 
the activity of CDK2, as well as CKII, is necessary for the stability of E7. Finally, we 
identified an interaction between HPV-16 E2 and E7 with the cellular oncoprotein, 
Mdm2. Mdm2 appears to destabilise E7 targeting it to proteasome-mediated 
degradation at PML bodies. The stability of E7 in cells that have reduced expression 
of Mdm2 is markedly increased indicating that the expression of Mdm2 indeed 
destabilises E7. In the case of the Mdm2 interaction with E2, we observe that E2 
inhibits Mdm2 mediated degradation of p53 and pRB and that the expression of Mdm2 
enhances E2’s transcriptional activity and induces its re-localisation at specific 
structures within the nucleus. Overall, our findings expand our knowledge of the 
regulation of virally encoded proteins both through direct protein-protein interactions 
between themselves and through their interactions with cellular proteins.
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Cancer and Human Papillomaviruses (HPVs)
Cancer is a genetic disease that is mainly characterised by indefinite cell growth 
and division capacity (Vogelstein & Kinzler, 2004). Approximately 10 million new 
cancer cases are estimated to occur every year by the W orld Health Organisation. 
The development of cancer is a multi-step event and involves the deregulation of 
multiple cellular pathways which eventually leads to a wide range of molecular and 
clinical diagnoses. Despite the variability of the disease, malignant cells appear to 
share a number of physiological features (reviewed by Hanahan & Weinberg,
2000). These include undisturbed cell growth, deregulation of apoptotic machinery, 
limitless replication capacity and metastatic tendency. In addition, most cancer 
cells have abnormalities in their genomes and share common deregulated 
molecular pathways, for example the pRB and p53 pathways, which have been 
highlighted as major targets of all DNA tumour viruses (Klein, 2002).
A number of factors trigger the development of cancer, and when identified, these 
can serve as tools to understand cancer progression and, most importantly, for the 
development of therapy. Up to 15% of human cancers are associated with viruses 
(Gatza et al, 2005). One example of this is cervical cancer; the second largest cause 
of cancer deaths in women with an estimated half a million new cases in the year 
2002 half of which were fatal (Parkin, 2006). Infection with Human Papillomavirus 
(HPVs) has been detected in virtually all cervical cancer cases. HPVs can also infect 
other epithelial sites and are thus linked to a number of clinical outcomes including 
benign warts of the skin, non-melanoma skin cancer in inherited epidermodysplasia
3
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verruciformis patients and a number of head and neck cancers (Gillison & Shah,
2001). In the cervix, infection with only certain types of papillomaviruses, termed 
high-risk HPVs (such as HPV-16, -18 and -31), can contribute to the development 
of cancer. Their low-risk counterparts (such as HPV-6 and -11) also infect the 
mucosal epithelium and induce the development of genital warts; however they are 
rarely associated with malignant lesions.
The development of cervical cancer in the absence of HPV infection is extremely 
rare. Human cervical carcinoma cell lines that are HPV-negative were found to 
harbour mutations in both p33 and pRB  sequences, the major targets of high-risk 
HPV oncoproteins E6 and E7, respectively (Scheffner et al, 1991). In contrast, p53 
and pR B  are invariably wild-type in HPV-positive cells, indicating the importance 
of disrupting these pathways in cervical carcinogenesis as well as explaining the 
rarity of non-HPV induced cervical cancers. The expression of E6 and E7 directly 
contributes to the progression of cervical cancer in HPV infections. E6 and E7 
support the viral life cycle by providing a cellular environment conducive to viral 
replication. Both proteins have multiple cellular binding targets (Figure l) and act 
cooperatively to induce cell cycle progression and inhibit apoptosis, mainly by 
disrupting the p53 and pRB pathways (Munger et al, 2004). However, their 
uncontrolled expression is directly associated with the development of cervical 
abnormalities and, ultimately, malignant progression. Experimentally, the 
combined activities of E6 and E7 induce the development of tumours in mice and 
the immortalisation of primary human keratinocytes (Matlashewski et al, 1987; 
Riley et al, 2003). Furthermore, in HPV-positive cell lines, inhibiting the 
expression of both proteins either transcriptionally, by the viral transcriptional 
regulator E2, or post-transcriptionally, using RNA interference (RNAi)
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F igure  1. C ellu lar pathw ays d isru p ted  by h igh -risk  H PV  E6 and E7. Arrows 
connect various proteins in a pathway, where pointed ends indicate activation, 
blunt ends indicate inhibition of activity and dashed lines indicate transcriptional 
regulation.
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technology, results in the inhibition of cell growth and the induction of apoptosis 
(Dowhanick et al, 1995; Yoshinouchi et al, 2003).
The phenotypic effects induced by the HPV oncoproteins on the cell overlap with 
some of the major physiological characteristics of a cancerous cell (Table l) (as 
reviewed by Hanahan & Weinberg, 2000). The E7 protein induces cellular 
proliferation by degrading pRb and by disrupting the activity of cyclin-dependent 
kinase inhibitors, p21 and p27, thereby activating transcription factors required for 
G l/S-phase progression (Dyson et al, 1989; Funk et al, 1997). E7 can also directly 
abrogate normal centrosome replication which can result in increased genetic 
abnormalities and genome amplification (Duensing & Munger, 2003). On the other 
hand, E6 plays a role in circumventing apoptotic pathways induced by the activities 
of E7 through the degradation of key pro-apoptotic proteins, such as p53 and Bak 
(Scheffner et al, 1990; Thomas & Banks, 1998). E6 also transcriptionally 
upregulates hTERT, the catalytic subunit of telomerase, thereby ensuring 
increased replicative competence of the cell by maintaining chromosome ends 
(Klingelhutz et al, 1996). Moreover, both E6 and E7 can modulate cell signalling 
cascades by desensitising cells to growth-inhibitory factors, such as TG F-beta and 
IGFBP-3 (Favre-Bonvin et al, 2005; M annhardt et al, 2000), and by upregulating 
stimulatory growth signals, such as the PKB pathway, resulting in increased 
expression of proliferatory genes even in the absence of growth factors (Pirn et al, 
2005). As cells progress into a tumorigenic state, they lose cell-cell contact and 
thus attain a state of uncontrolled cell division and high mobility. E6 is thought to 
contribute to this stage of cancer development by degrading certain PDZ- 
containing proteins which are components of cell junctions, such as Scribble, D ig 
and MAGI (Massimi et al, 2004).
5
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T able 1: Various pathways regulated by high-risk HPV oncoproteins; E6 and E7.
Cancer cell 
phenotype
cellular pathway 
involved
High-risk viral protein 
action Reference
Deregulation of 
apoptosis
p53 and Bak pro- 
apoptotic pathways
E6 induces degradation of 
both p53 and Bak
(SchefFner et al, 1990; 
Thomas & Banks, 1998)
Undisrupted cell 
growth pRB pathway
E7 induces degradation of 
pRB, and other pocket 
proteins
(Boyer et al, 1996)
Auto-regulated 
growth signalling
PKB signalling 
cascade
16E7 appears to 
upregulate PKB pathway
(Menges et al, 2006; Pim 
et al, 2005)
Renewable 
replicative capacity
Telomerase
activity
E6 increases hTERT 
transcription (Klingelhutz et al, 1996)
Metastasis Disruption of cell­cell junction
Possible involvement of 
PDZ-containing proteins- 
degradation by E6
(Massimi et al, 2004; 
Simonson et al, 2005)
H P V  infection is essential but insufficient
The majority of HPV infections are immunologically cleared from the infected 
individual (Jenson et al, 1991); in cases of persistent viral infection there is a long 
latency period of many years between initial infection with HPV and the 
development of premalignant lesions. In addition, exposure to external stimuli, 
such as oestrogens or UV radiation, is required to promote tumour progression 
induced by HPV oncoproteins in animal models. These two observations suggest 
the contribution of additional factors to the development of HPV-induced 
malignancies (Bosch et al, 2002). These may include unidentified hereditary risk 
factors (Hemminki et al, 1999; Magnusson et al, 1999), association with other 
diseases such as epidermodysplasia verruciformis (Harwood & Proby, 2002) and 
immune suppression (Palefsky, 2006; Petry et al, 1994). Other environmental 
cofactors include the prolonged use of hormonal contraceptives, high parity (full 
term pregnancy) and cigarette smoking (Bosch et al, 2006).
6
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The viral life cycle
The Virus
Papillomaviruses belong to the Papillomaviridae family, which together with other 
viruses such as Herpesviruses and Adenoviruses are classified as DNA tumour 
viruses. To date, more than 100 different subtypes of papillomaviruses have been 
identified, varying in their host species, sites of infection and clinical diagnosis. All 
papillomavirus genomes consist of a double-stranded circular DNA molecule, 
around 7.9Kb in size, contained within the viral capsid (Zheng & Baker, 2006). The 
viral genome can be divided into three main regions; non-coding, early-coding and 
late-coding (Figure 2). The non-coding region (Long Control Region, LCR, or 
Upper Regulatory Region, URR) contains an origin of DNA replication and a 
number of transcription regulatory sites. Viral non-structural proteins (E l, E2, E4, 
E5, E6 and E7) are encoded by the early-coding region, meanwhile structural 
proteins (Ll and L2) are encoded by the late-coding region. The additive size of the 
virus open reading frames plus the LCR exceeds the total size of the viral genome 
and therefore a number of coding sequences are overlapping. In addition, virally 
encoded transcripts undergo multiple splicing events which expands the potential 
number of viral gene products (Zheng & Baker, 2006).
The association between papillomavirus life cycle and its host
Papillomaviruses are strictly epitheliotropic and this tissue tropism could be, in 
part, due to the expression of certain epithelia-specific transcriptional factors which 
are essential for viral gene expression (Bedrosian & Bastia, 1990). These include
7
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KRF-l (Mack & Laimins, 1991), Epoc-1 (Yukawa et al, 1996) and PEF-1 
(Fergusson & Campo, 1998). In addition, papillomavirus infection is intimately 
associated with the differentiation of its host tissue. Viral gene expression is 
regulated differentially through the life cycle of the infected tissue, which 
influences viral genome amplification and the production of viral particles 
(Doorbar, 2005).
The normal life of the epithelial cells involves the progression of actively dividing 
basal stem cells into a terminally differentiated, cell cycle arrested and division- 
incompetent state. In the upper layers of the epithelial strata, cells eventually 
undergo nuclear breakdown and keratin accumulation, and are shed into the 
surrounding environment. The association between the virus life cycle and its host 
cell differentiation program is highly significant since papillomaviruses are non- 
lytic and the release of viral particles ultimately depends on the shedding of 
epithelial squamous cells from the upper layers of the cutaneous or mucosal 
epithelium (Figure 3a). Papillomaviruses, however, express proteins which can 
delay the cell cycle exit of differentiating epithelial cells and thereby ensure the 
prolonged maintenance of a cellular environment that can support viral genome 
replication.
The papillomavirus life cycle and its possible consequence of cancer progression 
are discussed below. There are considerable differences from one virus type to 
another in the actual sequence of events: here the main focus will be on the life 
cycle of high-risk HPV types (e.g. H PV-16, -18 and -31).
F igure  2. O rgan isa tion  o f  H P V -16 genom e. The six early coding 
sequences (E1-E7), the late coding sequences (Ll and L2) and the LCR 
are shown. Numbers indicate the nucleotide at which each functional 
sequence starts (adopted from NCBI; GenBank accession number 
NC_001526). The early (p97) and late (p640) prom oters are represented 
by arrows. A magnification of the LCR shows the various E2 binding 
sites (E2BS), numbered from 1 to 4, as well as the E l (ElBS), spl and 
TATA -box binding sites.
Virion assembly 
and release
Viral genome 
amplification
S-phase induction
Site of infection, low-copy 
number, viral genome 
segregation
Cornified
stratum
Supra-basal 
layer
Basal
layer
b)
F igure  3. H PV  life cycle, a) A model of the epithelium is shown here along 
with the HPV life cycle. HPV gain access to the basal cells through micro­
traumas. As these cells divide, one daughter cell starts to migrate to the supra- 
basal layer while another remains undifferentiated. By segregating their 
genomes equally in mitosis, HPV can both maintain viral infection in the basal 
cells and progress into the upper epithelial layers where viral genome 
amplification (green), virion assembly (blue) and release (brown dotted blue) 
take place. The expression of E6 and E7 is im portant for S-phase induction 
(red) in terminally differentiated cells (grey), b) HPV-induced malignancies. 
Continual expression of E6 and E7 and loss of expression of other viral 
proteins. The normal differentiation of the epithelium is disrupted.
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Infection and Early Stages (E l and E2)
Initial infection of papillomaviruses probably occurs through microtraumas in the 
upper layers of the epithelia which provide the virus with access to lower basal 
cells. The viral structural proteins, L l and L2, mediate virion uptake into the cell 
by endocytosis and viral genome entry into the nucleus (Day et al, 2003). In these 
cells, viral episomes are maintained at a low copy number of between 10-200 copies 
per cell (De Geest et al, 1993; Stanley et al, 1989). The virally expressed helicase 
E l plus the transcriptional activator E2 are thought to be required at this stage of 
the viral infection. Both E l and E2 are important for the replication of viral 
episomes and E2 is additionally involved in the control of viral gene expression and 
genome segregation.
E2 is a nuclear protein of around 45 kDa in size and consists of a transactivation 
domain in the N-terminal half of the protein, a middle non-conserved hinge region 
and a C-terminal domain that mediates DNA binding and protein dimerisation 
(Figure 4a). Alternative splicing of the E2 protein can also produce shorter forms 
that lack the N-terminal region. Full length E2 binds as a homodimer specifically 
to a consensus palindromic sequence, ACCNeGGT, through its C-terminal DNA 
binding domain (Androphy et al, 1987). Several E2-binding sites are present in the 
LCR of the viral genome, ranging from 4 sites in HPV up to 17 sites in Bovine 
Papillomavirus Virus (BPV). In HPV genomes, two E2-binding sites flank the viral 
origin of replication (ori), a third site lies directly upstream of the early promoter 
(p97 in HPV-16 and pl05 in HPV-18) which controls the expression of E6 and E7 
(Rohlfs et al, 1991; Sang & Barbosa, 1992), and a fourth site lies at the 5’ end of the 
LCR (Figure 2b). Binding of E2 to the LCR results in a structural bend of the DNA
9
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helices and facilitates the binding of both a number of transcription factors for viral 
gene expression and the E l helicase to the viral ori for the initiation of DNA 
replication (Thain et al, 1997).
In addition to the E2 binding sites, viral gene expression is regulated through 
multiple regions within the LCR including the TATA box and spl binding site 
(Gloss & Bernard, 1990). The binding of E2 proteins from HPV-16 and -18 was 
shown to both activate and repress expression of viral genes from the early 
promoter in a dose-dependent manner (Bouvard et al, 1994b). E2 binds with the 
highest affinity to binding site number four in the LCR (Figure 2) through which it 
can activate transcription of the early promoter (Steger & Corbach, 1997). At high 
levels of E2, it is thought that transcriptional repression takes place as E2 occupies 
all of its four binding sites. This results in the displacement of TATA-Binding 
Protein (TBP) and spl, both of which are required for transcriptional activation, 
from their binding sites in the LCR (Dong et al, 1994; Tan et al, 1992). 
Furthermore, methylation of the E2 binding sites in the LCR, which occurs 
differentially through the life cycle of the virus, inhibits the binding of E2 to the 
viral early promoter and can further regulate viral gene expression (Kim et al,
2003).
The activities of E2 may be regulated through sequences within its hinge region. 
In BPV E2, a Casein Kinase II (CKII) phosphorylation site has been identified at 
serine 301 which lies within the hinge region (Penrose et al, 2004). 
Phosphorylation of this site results in a structural change of the E2 protein and 
increases its proteasome-mediated degradation. Mutations of this serine in BPV-1 
E2 result in a more stable E2 protein and consequently an increase in the viral
10
a)
Transcriptional Transactivation 
Binding to E l and M itotic Chromosomes
Hinge DNA Binding and 
Dimerisation
249 365
(BPV) CKII
phosphory la tion
(H P V -1 1 )  NLS
F igure  4. T h e  E2 p ro te in , a) A cartoon depicting the main domains of HPV- 
16 E2 protein including the transcriptional transactivation domain and the E l 
and chromosome binding region at the N-term inal half, the middle flexible 
hinge region and the DNA binding and dimerisation domain at the C-term inal 
half Additional sites that are identified on other E 2 proteins are shown 
underneath, b) Viral genome segregation mediated by E c2 which binds as a 
dimer to the viral genome through its N-term inal end and to mitotic 
chromosomes through its C-terminal end.
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DNA copy number. The CKII consensus sequence is not conserved in HPV E2 
proteins; however, H PV -18 E2 is also degraded through the proteasome but this 
seems to involve sequences within its N-terminal domain (Bellanger et al, 2001). In 
addition, the localisation of E2 in or out of the nucleus could serve as an additional 
mechanism by which its activities can be controlled. The nucleus is the main 
cellular compartment where E2 can exert its major activities. Nuclear localisation 
of proteins can be controlled through the presence of nuclear localisation or nuclear 
export sequences (NLS or NES, respectively). In H PV -11 E2, an NLS was 
identified in the hinge region (Zou et al, 2000), meanwhile in HPV-16 E2 the NLS 
is present in the C-terminal domain (Klucevsek et al, 2007). H PV -18 E2 
additionally contains an NES in its N-terminal domain which, through an unknown 
mechanism, permits the shuttling of the protein in and out of the nucleus (Blachon 
et al, 2005).
Viral genome replication
In the infected basal cells, E2 plays a primary role in viral genome replication by 
recruiting the viral helicase, E l, onto the origin of replication (Mohr et al, 1990). 
E l is 73 kDa in size, it possesses both helicase and ATPase activities and is 
important for both the initiation and the progression of viral DNA replication. The 
N-terminal end of E l mediates both its DNA binding and nuclear localisation, 
while ATPase/Helicase activities, oligomerisation, DNA polymerase a  and E2 
binding are attributed to the C-terminal end. On its own, E l has a low affinity for 
binding DNA, whereas in the presence of E2 this is greatly increased. Due to the 
highly conserved E2 DNA recognition sequence, E l and E2 proteins from one
11
Introduction
virus type can mediate the replication of the viral genome from a different 
papillomavirus type. However, mixtures of the E l and E2 proteins from two 
different HPVs mediate genome replication much less efficiently than when E l and 
E2 are from the same HPV type, suggesting a degree of conservation in the E l/E 2  
interaction (Gopalakrishnan et al, 1999; Zou et al, 1998). This specificity is 
determined by the E l protein and, specifically, by its ATPase domain. Thus, 
replacing just the ATPase domain of HPV-16 E l with the ATPase domain of 
HPV-11 E l restores its cooperative DNA replication activity with HPV-11 E2 
(Zou et al, 1998).
After being recruited to the ori by E2, further E l molecules are recruited to form 
dihexameric structures on the DNA. This process requires ATP hydrolysis 
(Sanders & Stenlund, 1998) and its disruption interferes severely with DNA 
replication (Schuck & Stenlund, 2005). To allow the replication forks to initiate, E2 
must first be displaced from the ori. This takes place in an ATP-dependent manner 
through the combined activities of the E l helicase (Sanders & Stenlund, 1998), 
cellular heat shock proteins (HSP70 and HSP40) (Lin et al, 2002) and binding of 
E l to topoisomerase 1 (Conger et al, 1999; Masterson et al, 1998). The assembly of 
E l complexes on DNA causes major structural changes in the DNA, resulting in 
DNA melting (Chen & Stenlund, 2002). Furthermore, the binding between E l and 
the primase subunit of DNA polymerase a is important for recruitment of the 
cellular DNA replication machinery to the viral origin (Masterson et al, 1998). 
DNA unwinding then proceeds, which requires topoisomerase 1, single stranded 
DNA binding protein (RPA) and ATP (reviewed by Stenlund, 2003). Replication is 
then thought to proceed in a bi-directional theta mode, maintaining viral genomes 
as low copy number episomes in the basal layer (Flores & Lambert, 1997).
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A direct role for other viral proteins in viral genome replication can be postulated. 
The p53 protein can act as an inhibitor of viral DNA replication; this inhibition 
involves the DNA binding domain of p53 but not the transactivating domain (i.e. 
excludes its apoptotic and cell arrest functions) (Lee & Laimins, 2004; Lepik et al, 
1998; Massimi et al, 1999; Thomas et al, 1999b). The activity of E6 in inducing the 
degradation of p53 is well documented and it may thus enhance viral DNA 
replication. In addition, E7 might play a role in increasing the activity of E l by 
upregulating CDK2/cyclin E activity (see below). CDK2/cyclin E-mediated 
phosphorylation of E l is known to be important for viral replication (Lin et al, 
2000; Ma et al, 1999) since this regulates E l localisation in the nucleus (Deng et al,
2004).
Viral genome segregation
As basal stem cells divide, one daughter cell migrates into the upper epithelial cell 
layer while the other remains as a reserve stem cell (Watt, 1998). In the case of 
papillomavirus infection, the viral episomes are required to segregate equally upon 
basal cell division to ensure both genome maintenance in the epidermal stem cells 
and a productive viral life cycle in the upper epithelial layers. One way of doing this 
would be to segregate the viral genomes using chromosome arms as vehicles 
(McBride et al, 2004; McBride et al, 2006). The phenomenon of viral genome 
segregation is shared by a number of viruses but the mechanism appears to be not 
conserved, neither between different viruses nor even within different viral 
subtypes (Oliveira et al, 2006). Epstein-Barr Virus (EBV), Human Herpes Virus 
(HHV) and Herpesvirus Saimiri (HVS) each encode proteins which mediate the
13
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binding of their viral episomes to various cellular targets on mitotic chromosomes 
(Table 2). Such redundancy in the utilisation of genome segregation strategies of 
very different viruses may highlight the essential role of this process for the 
completion of the viral life cycle.
The first evidence that a papillomavirus-encoded protein can associate with mitotic 
chromosomes came from a study of BPV E2 (Skiadopoulos & McBride, 1998). This 
was based on previous work showing that E2 is required for the long-term 
maintenance of minichromosomes containing E2 binding sites in a mode that is 
independent of its replication activity (Piirsoo et al, 1996). BPV-1 E2 was shown to 
mediate episome segregation by acting as a bridge between viral genomes and 
dividing chromosomes (Figure 4b). This is achieved through the C-terminal DNA 
binding domain of E2 attaching to the viral DNA, whilst at the same time the N- 
terminal domain interacts with the chromatin-binding and bromodomain- 
containing protein, Brd4 (McPhillips et al, 2005; You et al, 2004). Brd4 is a nuclear 
protein that attaches to acetylated chromatin during interphase and mitosis and 
plays a role in regulating transcription and cell growth (Dey et al, 2003). Although 
E2 proteins from a number of HPV types can bind to Brd4, it is still not certain 
whether Brd4 is essential for their viral genome segregation (Abbate et al, 2006; 
McPhillips et al, 2006). One study has shown that this interaction seems to be 
more relevant for HPV E2 mediated transcription rather than chromosome 
localisation (McPhillips et al, 2006). Further studies have highlighted alternative 
ways by which HPV E2 proteins may mediate episome segregation. Detailed 
fluorescence microscopy has shown that E2 from the low-risk HPV-11, and 
possibly other HPV types, associates with the mitotic spindle apparatus rather than 
the chromosome arms during mitosis (Dao et al, 2006; Van Tine et al, 2004). Other
14
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studies propose alternative cellular proteins, such as mitotic kinesin-like protein 2 
(MKlp2) (Yu et al, 2007) and ChIR (Parish et al, 2006), as possible mediators of 
HPV E2 interaction with mitotic chromosomes. Such variations between different 
studies might be due to differences in experimental procedures. Alternatively, 
given the example of the LANA protein of HHV8, which uses a number of different 
cellular proteins to mediate its episome segregation (Krithivas et al, 2002), it is 
possible that the equivalent HPV E2 function is also mediated by more than one 
cellular protein. Therefore, the effects of disturbing the interaction between E2 and 
one protein partner might actually be masked by the interaction of alternative 
cellular partners, indicating a zdegree of redundancy.
Table 2: Various virally encoded proteins th a t are involved in viral DNA segregation
Virus T ethering protein Cellular targe t Reference
Hum an Papillom avirus 
(H PV ) E2
Brd4 (possibly  
additional targets) (You et al, 2004)
Epstein-Barr Virus 
(EBV)
E B-nuclear an tig en -1 
(E B N A -l)
P 40  (nucleolar 
proliferation antigen
(W u et al, 2000)
Hum an H erpes V irus 8 
(H H V 8)
L atency-associated  
nuclear antigen  
(LA NA )
H iston e H i ,  D ek, 
M eC BP, Brd2, 
H 2A -H 2 B
(Barbera et al, 2006; 
Krithivas et al, 2002; 
Viejo-Borbolla et al, 2005)
H erpesvirus saimiri 
(HVS) O R F73
p (Calderwood et al, 2004)
Lower Epithelial layer and Proliferative stage (ES, E 6  & E7)
As the infected basal cell layers of the epithelia start to differentiate, their 
replicative capacity is greatly reduced (W att et al, 2006). In these cells viral 
episomes are maintained at high copy number, and a replication switch into rolling 
circle mode is observed (Flores et al, 2000). In this phase, the E6 prom oter is 
activated, which results in the enhanced expression of E l, E2, E 5, E6 and E7. 
Three early gene products, E5, E6 and E7, possess proliferation stimulatory effects
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which contribute to restoring the replicative capacity of the differentiated cells. E6 
and E7 are expressed from a bicistronic mRNA (Tan et al, 1994) and their 
cooperative function in stimulating cell cycle progression is the most studied.
E7 is a small acidic phosphoprotein, with an isoelectric point of about 4.0, and 
shares some sequence homology with the Adenovirus E la  protein and the simian 
virus 40 large T  antigen (LT) (Chellappan et al, 1992; Phelps et al, 1988). E7 is 98 
amino acids in length (predicted molecular weight of llkD a) and contains a zinc- 
binding domain in the C-terminal region (Rawls et al, 1990) whose structural 
integrity is necessary for the activity of E7 (McIntyre et al, 1993). High-risk HPV 
E7 has multiple cellular binding partners and can interfere with multiple cellular 
pathways. The main activity of E7 is to bind and inactivate the pocket protein 
family members; pRB, pl07, and p i 30, and thus, by activating E2F transcription 
factors, it induces S-phase progression and restores the DNA synthesis machinery 
necessary for viral replication, (reviewed by Felsani et al, 2006). E7 also regulates 
cellular transcription by binding to the TBP (Massimi et al, 1997), TBP-associated 
factors (Mazzarelli et al, 1995) and members of the AP-1 transcription factor 
family such as c-Jun (Antinore et al, 1996). In addition, E7 stimulates cell cycle 
progression and transcription by inhibiting the activity of the cyclin-dependent 
kinase inhibitors p21 and p27 (Funk et al, 1997) and histone deacetylases (Brehm et 
al, 1999). Furthermore, cell cycle arrest induced by growth inhibitory signals, by 
DNA damage or by serum deprivation can all be abrogated by the activities of E7 
(Demers et al, 1996).
The expression of E7 is critical for the viral life cycle: engineered viral genomes 
with disrupted expression of the E7 coding sequence do not support a productive
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life cycle (Flores et al, 2000; Oh et al, 2004b; Thomas et al, 1999a). The specific 
importance of each of the above interactions of E7 in the context of the viral life 
cycle is, up to this point, largely unknown. In a recent study, the activity of wild- 
type E7 protein was monitored in a mutant pRB background that is defective in 
binding E7 but in which it retains its other activities (Balsitis et al, 2005). This 
study has shown that the interaction between E7 and pRB is important for the 
induction of DNA synthesis and for overcoming DNA damage-induced cell cycle 
arrest, therefore the disruption of pRB function by E7 is crucial for providing the 
cellular environment important for viral genome amplification. In addition to its 
function in controlling G l/S-phase progression, pRB also plays a role in cellular 
differentiation (Nguyen et al, 2004; Nguyen & McCance, 2005). Thus, E7 targeted 
degradation of pRB may also play a role in delaying the differentiation of infected 
epithelial cells and thereby extending the period during which viral replication can 
take place.
E7 exhibits pro-apoptotic activities on the cell (Kaznelson et al, 2004; Stoppler et 
al, 1998). The degradation of pRB and unscheduled DNA synthesis triggered by 
E7 may lead to an increase in p53 levels in the cell. One way in which this may 
occur is through E2F-mediated upregulation of the expression of p l4A RF which 
acts as an inhibitor of Mdm2, and thereby inhibits Mdm2-mediated degradation of 
p53. Indeed, cells expressing E7 have elevated p53 levels (Demers et al, 1994; 
Jones & Munger, 1997) which is transcriptionally active as detected by the 
increased expression of p53 regulated genes, such as p21 (Seavey et al, 1999) and 
Mdm2 (Thomas & Laimins, 1998). In these cells, however, the activity of p21 in 
mediating cell cycle arrest is inhibited (see below) and the Mdm2-p53 binding is 
disrupted (Seavey et al, 1999).
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E6 plays an important role in preventing the p53-mediated apoptosis induced as a 
result of E7’s activities. The E6 protein is around 150 amino acids in length and 
contains two zinc binding fingers that are structurally similar to that found in E7. 
By binding to a HECT domain-containing ubiquitin ligase, named E6-associated 
protein (E6-AP), E6 enhances the targeting of p53 for proteasome-mediated 
degradation (Scheffner et al, 1993). The normal cellular targets of E6-AP are 
largely unknown, but mutations that disrupt its ubiquitin ligase activities or 
chromosomal deletions in its coding sequence are associated with the neurological 
disorder Angelman syndrome (Cooper et al, 2004). Viral genomes with complete 
disruption of E6 expression or which harbour mutations in the p53 binding region 
of E6 fail to maintain viral episomes (Park & Androphy, 2002; Thomas et al, 
1999a). However, the episomal maintenance of viral genomes that harbour mutants 
of E6 defective in p53 binding can be rescued upon the disruption of the E7-pRB 
interaction, thus indicating the importance of the balanced activities of both 
oncoproteins (Park & Androphy, 2002). This rescue is only partial with respect to 
wild-type genomes, therefore full activities of both E6 and E7 are essential to 
ensure stable genome replication in infected epithelial cells. E6 also prevents 
apoptosis by interfering with Bak (Thomas & Banks, 1998), Bax (Li & Dou, 2000; 
Vogt et al, 2006), Fas (Filippova et al, 2004) and c-myc (Gross-Mesilaty et al, 
1998), all of which are pro-apoptotic, and it also stimulates the anti-apoptotic NF- 
kB pathway (James et al, 2006). As well as supporting cellular survival and 
proliferation, E6 increases telomerase activity, which is absent from somatic cells, 
and thus prevents chromosome end ligation and mitotic failure (Klingelhutz et al, 
1996; Plug-DeMaggio et al, 2004). The relevance of this function for the viral life 
cycle remains to be determined (Park & Androphy, 2002).
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In addition to E6 and E7, E5 also has proliferation stimulating activity, and can 
cooperate with E7 to induce the proliferation of human keratinocytes (Bouvard et 
al, 1994a). Although E 5 is the major transforming protein in BPV-1, in H PV -16 it 
has only a subtle role in the productive stages of papillomavirus infection. 
Engineered viruses mutated in E 5 expression undergo reduced DNA synthesis in 
the suprabasal cells, but viral genome amplification, late gene expression and virion 
production are unaffected (Genther et al, 2003). E5 is a hydrophobic membrane 
protein that localises to various cellular organelles including the Golgi apparatus 
and the endoplasmic reticulum. It functions primarily by stimulating Epidermal 
Growth Factor Receptor (EGFR) activity which results in increased MAP kinase 
and Protein Kinase C signalling. Epithelial cells are particularly rich in EGFR, and 
E5 transforming activity is reduced in cells lacking EGF receptors (Pirn et al, 
1992). E 5 probably exerts its activity by inducing endosome alkalisation and the 
enhanced recycling of EGFR into the cell membrane (Straight et al, 1995). Other 
E5 functions also include increasing host cell resistance to apoptosis through the 
activation of two survival signalling molecules, PIsK  and E R K l/2  MAPK (Zhang 
et al, 2002), and contributing to immune evasion by the down-regulation of MHC 
class II cell surface expression (Zhang et al, 2003).
Genome amplification
Replication of the viral genome greatly increases in the upper middle layer of the 
epithelium, in a region that overlaps with increased cellular proliferative capacity 
induced by the expression of E6 and E7 (Figure 3a). As mentioned above, E2 
protein levels determine its transcriptional modulation of the early viral promoter
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from which E6 and E7 transcription is controlled. At the stage of viral genome 
amplification, E2 (as well as E l) is expressed at increased levels and therefore the 
expression of E6/E7 from the early promoter is expected to be eventually reduced. 
The activation of the late promoter (p670 in HPV-16 which lies within the E7 
coding region) takes place at this stage and leads to the activation of E l, E2, E4 
and E5 expression (reviewed by Doorbar, 2005). While the expression of E l and 
E2 is important for viral genome replication (see above), the roles of E4 and E5 at 
this stage of the viral life cycle are still poorly understood.
E4 is highly expressed at this stage and its expression marks the beginning of the 
late events of the virus life cycle. The E4 ORF lies within the E2 sequence and the 
protein is expressed from transcripts that include a region within the E l coding 
sequence that has been spliced into the 5’ end of the E4 mRNA (Nasseri et al, 
1987). E4 is predominantly cytoplasmic and is highly insoluble due to its 
interaction with keratin structures (Doorbar et al, 1991). The N-terminal domain 
of E4 mediates its binding to keratin filaments, especially to keratin 18, a member 
of the type 1 intermediate filament family (Wang et al, 2004). This interaction 
results in collapse of the keratin network in the cell which is thought to delay 
epithelial terminal differentiation and therefore increase the viral replication 
capacity and assist viral egress (Doorbar et al, 1991). Another major activity of E4 
is the induction of a G2 arrest through the sequestration of active CDKl/CyclinBl 
into the cytoplasm (Davy et al, 2005). The exact advantage of this cell cycle arrest 
for the virus is not clearly understood. One possibility is that E4 prolongs 
suprabasal DNA synthesis and thus enhances viral genome amplification 
(Nakahara et al, 2002; Nakahara et al, 2005). Additional functionally uncertain 
activities of E4 include binding to a DEAD box RNA helicase (Doorbar et al, 2000)
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and to the mitochondria (Raj et al, 2004). The function of E4 is important for an 
optimal viral life cycle, as engineered viruses with disrupted E4 expression have 
been shown to have greatly reduced vegetative replication and late gene expression 
and therefore diminishes virion production (Peh et al, 2004; Wilson et al, 2005; 
Wilson et al, 2007).
Virion release and vaccination
At the upper layers of the epithelia, virions are produced by the assembly of viral 
genomes into icosohedral capsids. This requires the viral structural proteins, L l 
and L2, which constitute viral capsomeres at a ratio of 30:1 (Roden et al, 1996). L l 
is the major component of the capsid which can spontaneously assemble into virus­
like particles (VLPs) (Kirnbauer et al, 1993), while the L2 protein is required for 
efficient encapsidation of the viral genomes (Roden et al, 1996). In addition, L2 can 
redirect L l into promyelocytic leukaemia protein (PML) domains which most 
likely serve as sites for virion assembly (Day et al, 1998). The non-structural E2 
protein may also play a role at this stage by binding to viral genomes and 
enhancing their recruitment into the sites of assembly. This association of E2 with 
PML bodies is possibly mediated through its direct interaction with the viral L2 
protein (Heino et al, 2000).
The interesting ability of L l to natively assemble into VLPs has helped the 
development of a prophylactic vaccine against the high-risk H PV -16 and -18. The 
vaccine acts by inducing humoral immune response against the corresponding 
HPV-type infection (reveiwed by Roden & Wu, 2006). The use of a vaccine against
21
Introduction
HPV coat protein will, however, be ineffective in treating HPV-associated cancers, 
as these contain integrated genomes with disrupted L l and L2 expression. In this 
case targeting the continual expression of E6 and E7 is a more attractive approach 
(see below). Such approaches may include the use of blocking peptides (Sterlinko 
Grm & Banks, 2004), RNA interference (Bagasra, 2005) and stimulating cytotoxic 
T  lymphocytes to recognise infected cells (Sin, 2006).
HPV-induced malignancies
Only a very small fraction of high-risk HPV infections progress into high grade 
cervical neoplasia. This occurs especially in cases where viral infection is persistent 
and fails to be resolved by the immune system of the infected individual. In such 
cases, productive infection of the virus is supported only very poorly (Doorbar, 
2006; Middleton et al, 2003). The normal differentiation of host cells into the upper 
cornified layers is essential for virion production and release. Therefore, disrupting 
the normal epithelial cell differentiation into the upper layers is very 
disadvantageous for the virus. Avoiding such a catastrophic event in the 
papillomavirus life cycle requires fine regulation of its gene expression as well as 
the activity of the expressed gene products. Upregulation of both E6 and E7 
expression is generally seen in HPV-induced malignancies and viral DNA is 
usually found integrated into its host genome (Peitsaro et al, 2002). Integration 
often takes place in common fragile sites within the E2 sequence (Thorland et al, 
2003) resulting in the loss of E l, E2, E4, and E5 sequences and the upregulation of 
both E6 and E7 expression (Corden et al, 1999). There is no evidence that 
integration can be followed by a recombination event which restores viral
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episomes. The integration process by itself may result in genetic abnormalities of 
the host genome(Popescu & DiPaolo, 1990), but it is the continual expression of E6 
and E7 that has been extensively studied in relation to cancer progression. Both 
proteins can cooperate to induce immortalization of keratinocytes (Pei et al, 1994), 
with the expression of E7 alone sufficient to induce DNA synthesis in differentiated 
keratinocytes (Cheng et al, 1995) and invasive cervical cancer in transgenic mice 
(Riley et al, 2003).
Although the expression of E6 and E7 is essential for a productive viral life cycle, 
their uncontrolled expression can be deleterious for the virus. The induction of an 
uncontrolled cell division state by E6 and E7 in the upper epithelial layers results 
in a failure of cell differentiation and virion release (Figure 3b), even in the 
presence of intact viral episomes that continually express E l and E2 (Middleton et 
al, 2003). One way of controlling the expression of E6 and E7 is through 
transcriptional regulation by E2. In HPV-transformed cell lines containing 
integrated sequences of E6 and E7 and an intact LCR, E2 can strongly suppress 
transcription of both genes, resulting in cell growth inhibition (Dowhanick et al, 
1995; Francis et al, 2000; Goodwin & DiMaio, 2000). Therefore, the loss of E2 (and 
E l) expression not only results in loss of viral replicative capacity but also in loss 
of transcriptional control of the viral oncoproteins. In addition, cell growth 
inhibition by E2 can also occur in an E6/E7 gene-repression independent pathway 
(Demeret et al, 2003; W ebster et al, 2000). Therefore, the dramatic change in gene 
expression profiles that are induced by E2 (Thierry et al, 2004; Wells et al, 2003) 
may occur in an alternative pathway to the E2-LCR binding. These may involve 
the binding of E2 to various components of the cellular transcription machinery 
(Hadaschik et al, 2003; Rehtanz et al, 2004), or the presence of unidentified E2
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DNA binding sites in the promoter region of cellular genes that could allow E2 to 
influence cellular gene expression.
The difference between the potential capacity of low- and high-risk HPV 
oncoproteins to induce cancer progression may be correlated with the sequence of 
events during their respective life cycles (Doorbar, 2005). High-risk HPVs 
replicate their genomes in the upper epithelial layers and therefore viral gene 
products are important to stimulate the availability of cellular enzymes required for 
replication. Meanwhile the productive replication of low-risk HPV occurs at lower 
epithelial layers where the virus can utilise the more readily available cellular 
replication machinery. This is apparent in the difference in activity of E6 and E7 
encoded by high- or low-risk viruses. For example, the binding and inactivation of 
p53 and pRB by high-risk HPV E6 and E7, respectively, occurs at a much higher 
efficiency than that seen with the low-risk E6 and E7 proteins. In addition, using in 
vitro biological assays, low-risk HPV E6 and E7 exhibit very poor activities in 
comparison with their high-risk counterparts in inducing anchorage-independent 
growth in rodent fibroblasts and in cellular immortalisation of human 
keratinocytes (Barbosa et al, 1991).
The oncogenic activities of high-risk E6 and E7 will be discussed below. It is worth 
noting that cancer development generally involves the deregulation of multiple 
cellular pathways and the disruption of only a single gene product in each pathway 
(Vogelstein & Kinzler, 2004). HPV E6 and E7 can regulate multiple cellular 
pathways. Each oncoprotein, however, can result in the disruption of multiple gene 
products within a single pathway. Therefore, the activities of the high-risk HPV
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oncoproteins, to be discussed below, may occur only following certain post- 
translational modifications of the viral proteins or under certain cellular conditions.
E 6 transforming capacity
Although E7 is the more potent oncoprotein of high-risk HPV, the expression of 
E6 strongly enhances E7-induced cervical carcinogenesis in transgenic mouse 
models (Riley et al, 2003). Furthermore, the expression of E6 alone in the skin of 
transgenic mouse is sufficient for the development of carcinoma and its activities 
can result in the progression of benign E7-induced tumours into malignancies 
(Song et al, 1999).
E6 has multiple cellular binding partners and shares functional and sequence 
homology with a number of oncoproteins of other viruses including Adenovirus 
E40RF6 (reviewed by Mantovani & Banks, 2001). The E6 ORF contains a splice 
donor which alternatively splices into a number of downstream splice acceptor 
sites, thus producing a number of shorter forms of E6 denoted E6* I-IV (Doorbar 
et al, 1990; Schneider-Gadicke & Schwarz, 1986). These shorter forms of E6 have 
been implicated in regulating the functions of the full-length protein (Pirn et al, 
1997).
The inactivation of the p53 tumour suppressor is a phenomenon shared among all 
DNA tumour viruses, and in high-risk HPV infection it is mediated by the 
activities of E6. Whereas many viral oncoproteins, such as Adenovirus E1B-55K 
and Hepatitis B virus X proteins, inactivate p53 by sequestering it into inactive 
complexes, E6 functions by mediating proteasome degradation of p53. High-risk
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HPV E6 contains multiple contact sites that mediate the binding to p53 (Pirn et al, 
1994). In contrast, low-risk HPV E6 proteins bind and degrade p53 only weakly 
(Slebos et al, 1995; Storey et al, 1998). This also correlates with their low affinity 
binding to E6-AP, the ubiquitin ligase that mediates p53 degradation by the high- 
risk E6 proteins (Scheffiier et al, 1993). Loss of p53-mediated tumour suppression 
leads to early tumour development (Donehower et al, 1992) and certainly 
contributes to E6’s enhancement of E7-induced tumorigenesis (Song et al, 2000). 
p53 is a major transcriptional activator of cell cycle regulatory proteins and its 
prolonged inactivation causes dramatic changes in the cell, including alterations in 
the transcription of a number of genes (Kelley et al, 2005). Cells expressing E6 
have increased levels of PIKl which acts as a downstream signal from p53 to 
prevent cell cycle arrest and can induce chromosome mis-segregation (Incassati et 
al, 2006), which might contribute to the malignant phenotype as a result of E6 
expression. p53 inactivation by E6 is essential for supporting E6/E7 mediated 
immortalisation and for the inhibition of apoptosis (Horner et al, 2004; McMurray 
& McCance, 2004). In these assays, telomerase activation by E6 was shown to be 
dispensable, although increased telomerase activity can contribute to the induction 
of malignant transformation and prevent cell death (Chung et al, 2005). However, 
additional mutants of E6 that still retain their ability to disrupt p53 activities are 
unable to induce cellular transformation, thus indicating the requirement of 
additional E6 activities that mediate malignant progression (Liu et al, 1999; 
Nakagawa et al, 1995; Pirn et al, 1994).
In addition to p53 inactivation, E6 interacts with p300 and CBP which are 
transcriptional co-activators of key cell cycle regulatory proteins (Patel et al, 1999; 
Zimmermann et al, 1999). In the case of Adenovirus infection, targeting of
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p300/CBP by E l a is essential for its transforming activities (Turnell & Mymryk,
2006). p300 and CBP can acetylate histones, allowing the activation of gene 
transcription, and transcription factors, such as NF-kB, p53 and c-myc, modulating 
their activities (Iyer et al, 2004). The exact role ofp300/CBP inactivation mediated 
by E6 is unclear. However, E6 can complement the transformation activity of a 
p300-binding defective E la  mutant, suggesting that p300 binding by E6 might 
contribute to its transformation activities (Bernat et al, 2002). E6 can additionally 
regulate cellular transcription by binding and inactivating transcriptional effectors 
such as NF-kB and c-myc, which enhance escape from the immune response and 
avoid activation of apoptosis, respectively (Filippova et al, 2002; Gross-Mesilaty et 
al, 1998).
Additional cellular protein interactions of E6 are mediated through the extreme C- 
terminus sequences which are highly conserved among all high-risk HPV E6 
proteins. Deletion of this domain disrupts the ability of E6 to promote skin 
carcinogenesis in transgenic mouse models (Simonson et al, 2005). This conserved 
region of E6 contains a PDZ (PSD95, Dig and ZO-l) binding motif (XT/SXV). 
PDZ-containing proteins are a family of multifunctional proteins in which the PDZ 
domains confer protein-protein interaction capacity. E6 can interact with some 
members of this family, including Discs Large (Dig) (Gardiol et al, 1999), Scribble 
(Scrib) (Nakagawa & Huibregtse, 2000), MAGI (Glaunsinger et al, 2000), M U PPl 
(Lee et al, 2000), PTPN3 (Jing et al, 2007) and paxillin (Tong & Howley, 1997), all 
of which are involved in regulating various aspects of cell-cell adhesion and 
polarity. Several studies have shown that E6 can mediate the degradation of a 
number of these PDZ-containing proteins through the proteasome by recruiting 
the E6-AP ubiquitin ligase (Grm & Banks, 2004; Handa et al, 2007; Kuballa et al,
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2007; Matsumoto et al, 2006). The advantage of this activity of E6 in the context of 
the life cycle of HPV is still not clear. It appears, however, to be necessary for the 
early proliferation events and disrupted cell adhesion and differentiation exerted by 
E6 (Lee & Laimins, 2004; Nguyen et al, 2003).
E 7 transforming capacity
HPV E7 is arguably the most potent oncoprotein encoded by the virus. Using in 
vivo models in mice, the expression of E7 can lead to invasive cancers of the cervix 
(Balsitis et al, 2003; Herber et al, 1996; Riley et al, 2003). Post-transcriptionally, 
E7 can be regulated by both phosphorylation and the proteasome. At present, only 
Casein Kinase II (CKII) has been shown to phosphorylate E7 on its N-terminal 
domain (Barbosa et al, 1990) which has been shown to be essential to the 
transformation activity of E7 (see below). An additional phosphorylation site lies in 
the C-terminal domain of E7 that is phosphorylated in S-phase by an unknown 
kinase (Massimi & Banks, 2000). In addition, variation in the phosphorylation 
status of E7 was shown to affect the antigen recognition of the protein, suggesting 
that phosphorylation of E7 may regulate its secondary conformation and protein- 
protein interactions (Kee et al, 1998). More is known about proteasome-mediated 
degradation of E7 (Reinstein et al, 2000; W ang et al, 2001), where it has been 
shown that E7 interacts with the Skp-Cullin-F box (SCF) ubiquitin ligase complex 
(Oh et al, 2004a). This interaction results in increased ubiquitination of E7 and, in 
cells lacking a functional SCF complex, Skp2 - /-  M EF cells, E7 has an increased 
half-life of more than an hour compared with 30min in wild-type M EF cells. The 
SCF complex is involved in the degradation of many cell cycle regulated proteins
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including E2F-1, p27 and cyclin E (Nakayama & Nakayama, 2005; Petroski & 
Deshaies, 2005). Although most substrates of the SCF ligase are phosphorylated 
prior to ubiquitination, phosphorylation-dependent regulation of E7 ubiquitination 
by the SCF complex has not yet been investigated.
The localisation of E7 is still somewhat ill-defined within the cell. Indirect 
immunofluorescence in HPV-positive cell lines (Oh et al, 2004a) and subcellular 
fractionation (Sato et al, 1989) indicate that E7 is cytoplasmic. However, the 
nucleus is a physiologically important site for the major activities of E7 including 
the disruption of the pocket protein activities. Nuclear E7 has been detected using 
transformation assays of rodent fibroblast cells (Smith-McCune et al, 1999), 
epithelial raft tissues (Middleton et al, 2003) and transient transfection assays in 
HPV-negative cell lines (Guccione et al, 2002; Sato et al, 1989). No obvious NLS 
has been identified in the E7 sequence, and the mechanism of its nuclear 
localisation remains unidentified.
The E7 protein can be divided into three conserved regions (Figure 5); CRl-3, 
based on its sequence homology to other DNA virus oncoproteins; Adenovirus E la  
and SV 40 Large T  antigen (Phelps et al, 1988; Phelps et al, 1989). The CR2 and 
CR3 regions of HPV E7 mediate most of its described cellular protein interactions, 
however the full-length protein is critical for its optimal activity (Patrick et al, 
1994).
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CRl
The CRl constitutes the first 20 amino acids of HPV -16 E7, and this region is 
critical for its transforming potential (Brokaw et al, 1994). Substitution of the 
second residue of E7 (Pro2) and a deletion mutant A6-10 greatly reduces its ability 
to induce S-phase progression and cell transformation, although these mutants still 
retain their pRB binding activities (Demers et al, 1996). In addition, the Pro2 
mutation of E7 disrupts its ability to upregulate the activity of cyclin A which is 
mainly mediated through the CR2 region (see below) (Zerfass et al, 1995). Little is 
known about the mechanisms that lie behind the potential activities of the CRl 
domain of E7. Structural studies have shown that the N-terminal domain of E7 is 
highly disordered, so it might be speculated that mutations within this region 
would have little impact on the overall structure of the E7 protein (Ohlenschlager 
et al, 2006). To date, only a few proteins have been shown to bind to the CRl 
region of E7, these include p300/CBP-associated factor (P/CAF) (Huang & 
McCance, 2002) and a newly identified protein; p600 (Huh et al, 2005). P/CA F is 
important for the transcriptional activation of NF-kB family members which are 
involved in initiating cellular immune responses. The expression of E7 suppresses 
P/CAF-mediated activation of the NF-kB response that might be stimulated in 
response to viral infection. This activity of E7 is disrupted by mutating its second 
residue which is also required to mediate the binding with P/CAF, although an 
additional binding site can be found in the CR3 domain of E7 (Avvakumov et al,
2003). Meanwhile, the binding between E7 and p600 was identified using tandem 
affinity purification. p600 is essential for anchorage-independent growth of both 
HPV-negative and HPV-positive cell lines. It possesses a possible ubiquitin ligase
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F igure  5. T h e  E7 p ro te in . A model of HPV-16 E7 that highlights various 
regions involved in its post-translational modification, binding to cellular 
substrates and Zn-binding domain. The amino acid residues constituting each of 
the conserved regions (CR) of E7 are indicated and the cysteine residues 
mediating the Zn-binding finger are highlighted within the CR3. Various 
regions that mediate binding to cellular targets of E7 are highlighted by 
triangular boxes. Numbers indicate the amino acid residue from the start o f the 
E7 peptide.
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domain but its role in E7’s activities is still unclear. However its localisation in the 
cytoplasm may contribute to some of E7’s cytoplasmic functions.
CR2
The CR2 region of HPV-16 E7 spans amino acids 20 to 38. It contains an LXCXE 
motif, which confers binding to the pocket proteins, and a CKII phosphorylation 
site at residues 31 and 32. The CKII consensus site has been shown to be 
phosphorylated by CKII in vitro (Firzlaff et al, 1989). Mutations in the CKII 
phosphorylation site in HPV-18 E7 reduce its ability to promote S-phase entry of 
differentiated keratinocytes cultured in rafts (Chien et al, 2000) and impair the 
transforming activity of HPV-16 E7 (Barbosa et al, 1990). E7 phosphorylation by 
CKII may affect its stability or its interaction with cellular targets. The latter has 
been tested in the case of E7’s interaction with TBP which is enhanced by CKII 
phosphorylation of E7 (Massimi et al, 1996). Interestingly, the levels of cellular 
CKII inhibitors, MRP-8 and M R P-14, are reduced in HPV immortalised cells 
(Tugizov et al, 2005). Treating these cells with exogenous M R P -8 /14 complexes 
leads to E7 hypophosphorylation and growth inhibition. Although the levels of 
phosphorylated E7 are reduced in these experiments, they were not completely 
abolished, which indicates that E7 may also contain additional phosphorylation 
sites. Indeed, a second phosphorylation site is located at the C-terminal region of 
E7, which is differentially phosphorylated during the cell cycle (Massimi & Banks, 
2000).
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pRB binding
The binding and inactivation of pRB by E7 has been highlighted as one of the main 
functions of the protein. E7 from high-risk HPV types, as well as Adenovirus E la  
and SV40 LT, bind with high affinity to pRB, as well as to the other pocket protein 
family members p i07 and p i 30 (Davies et al, 1993; Zhang et al, 2006). The pocket 
proteins bind to and inhibit E2F-mediated transcription (reviewed by Cobrinik, 
2005). Their phosphorylation by cyclin dependent kinases (CDKs) inhibits their 
interaction with E2F, resulting in E2F transcriptional activation and cell cycle 
progression. Members of the pocket protein family are expressed in different tissue 
types and differ in their preferred targeted E2F members (Cobrinik, 2005). pRB 
specifically targets E2F 1-3 and is expressed in both proliferating and non­
proliferating cells. p l07 is predominantly expressed in proliferating cells and 
inhibits E2F4 activity, whilst p i 30 is predominantly expressed in non-proliferating 
cell types and inhibits E2F5 activity. The key roles of pl07 and p i 30 in cell cycle 
regulation are still not clear, and attention therefore has been focused on the E7- 
pRB interaction. The CR2 domain of E7 mediates its binding to the B-domain of 
pRB, with an additional contribution from the CR3 domain of E7 (Patrick et al, 
1994). E7 binds specifically to the hypophosphorylated form of pRB which is active 
in binding the E2F transcriptional factors (Imai et al, 1991). This binding results in 
disruption of pRB-E2F complexes and in destabilisation of pRB through 
proteasome-mediated degradation (Boyer et al, 1996; W ang et al, 2001). The 
disruption of pRB function by E7 results in an increased expression of cyclin A, 
cyclin E and CDK2 as a result of E2F-induced transcription. In addition, pl4ARF 
expression is increased, thereby inhibiting Mdm2 activity and stabilising p53 levels 
(Thomas & Laimins, 1998). The stabilisation of p53 can also occur through a
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pl4A RF independent pathway (Seavey et al, 1999). Furthermore, E2F activation 
results in increased levels of p21 and p i6, inhibitors of CDKs, but their negative 
effects on cell cycle progression is overridden by the role of the CR3 region of E7, 
which sequesters p21 into the cytoplasm and inhibits its activities (Westbrook et al, 
2002).
pRB binding is a characteristic function of high-risk HPV E7 proteins. M utants of 
E7 in the pRB binding site, however, still maintain their transforming ability 
(Jewers et al, 1992), meanwhile other mutants in the CR3 region (A79-83) which 
retain pRB binding, lose their immortalising phenotype (Massimi et al, 1997). 
Therefore, additional functions of E7 are also essential for its transformation 
activities (Demers et al, 1996; Jewers et al, 1992).
CR3
W hilst both the CRl and CR2 regions of E7 are relatively unstructured and 
flexible in solution, the CR3 region of E7 folds into a well-structured zinc-binding 
domain with a f}lf$2al/p3a2  topology that is also involved in protein dimerisation 
(Liu et al, 2006; Ohlenschlager et al, 2006). The presence of four cysteine residues, 
which are highly conserved between different E7 proteins, mediate the formation of 
the zinc-binding finger (Figure 5). The structural integrity of this region is 
required for almost all of the functions of E7 and the presence of a number of 
charged residues mediate the binding of multiple proteins to that region (M cIntyre 
et al, 1993). In addition to its role in binding p21 mentioned above, the CR3 region 
mediates the interaction with TBP (Massimi et al, 1997), TBP-associated factors
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(Mazzarelli et al, 1995), members of the AP-1 family of transcription factor family 
(Antinore et al, 1996), the p27 inhibitor of CDK (Funk et al, 1997), M2 pyruvate 
kinase (Zwerschke et al, 1999), Mi2(3 component of the histone deacetylase 
(HDAC) complex (Brehm et al, 1999) and DNA methyltransferase (Burgers et al,
2007). The precise contribution of many of the CR3 interactions in the context of 
E7-induced transformation is not clearly understood. These interactions, however, 
suggest that E7 can subvert chromatin remodelling and transcriptional complexes, 
thus controlling cellular proliferation. By binding to, and inhibiting the activity of, 
HDAC complexes, E7 can increase the expression of the E2F gene by enhancing 
acetylation of the E2F promoter (Zhang et al, 2004). This results in increased 
expression of E2F-responsive genes which plays an additional role in promoting 
cell cycle progression. Furthermore, the binding of E7 to c-Jun, a member of the 
AP-1 transcription factors, results in an increased transcriptional activity of c-Jun 
(Antinore et al, 1996). This interaction may be important for transcriptional 
activation of the HPV early promoter (see above) and is also important for E7’s 
transformation activity.
It is not clear whether the interaction between E7 and p21 occurs directly (Funk et 
al, 1997; Westbrook et al, 2002), although structural studies have shown that a 
synthetic peptide corresponding to the C-terminus of p21 can result in chemical 
shifts in the CR3 region of E7 (Ohlenschlager et al, 2006). The levels of p21 are 
elevated in the presence of E7, despite the E6-mediated repression of p53-induced 
expression of p21. The activity of p21, and of p27, is however inhibited in E7- 
expressing cells, which is essential for E7-induced cell cycle progression (Helt & 
Galloway, 2001; Jones et al, 1997). In the case of p2l (and possibly p27), E7 
sequesters it to the cytoplasm by inducing protein kinase B (PKB) phosphorylation
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of p21 and thus prevents its inhibitory activity in the nucleus (Westbrook et al, 
2002). This results in an elevated CDK2/cyclin E activity which is important for 
G l/S-phase transition. Increases in CDK2/cyclin E levels can also be caused by 
direct interaction of E7 with CDK2 (He et al, 2003), by increased cyclin E 
expression through E2F-mediated transcription, or by up-regulated PKB 
expression (Pim et al, 2005) which phosphorylates and relocalises p21 into the 
cytoplasm (Zhou et al, 2001).
Additional functions o fE 7  
Cell Signalling Activities
The role of E7 in regulating cell signalling is probably a reflection of some of its 
cytoplasmic functions (McCance, 2005). A recent interaction study has identified 
interaction between E7 and the Steroid Receptor Coactivator (SRC-l) (Baldwin et 
al, 2006). SRC-1 is an important intermediary in hormone-dependent gene 
expression. The expression of E7 induces the down-regulation of SRC-1-mediated 
transcriptional activation by retaining it in the cytoplasm and thus sequestering it 
from forming transcriptional regulatory complexes with P/C A F and p300 
(Baldwin et al, 2006). Although p300 and P /C A F have been shown to interact with 
E7 (Avvakumov et al, 2003; Bernat et al, 2003), they are not involved in the 
interaction between E7 and SRC-1. Other signalling pathways regulated by E7 
include the response to insulin-like growth factor (IGF-l). IGF-binding protein-3 
(IGFBP-3) is largely expressed in senescent cells and can block proliferation in
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response to IGF-1. E7 can bind and destabilise IGFBP-3 therefore inhibiting its 
pro-apoptotic functions in response to IGF-1 (Mannhardt et al, 2000).
E7 also upregulates PKB (or Akt) which is involved in cell proliferation and 
survival in response to a number of stimuli (Menges et al, 2006; Pirn et al, 2005). 
Upon its stimulation by growth factors, PKB is activated by phosphorylation and, 
in turn, phosphorylates a number of downstream nuclear targets such as p21, 
relocalising it to the cytoplasm, and the proapoptotic Bcl-2 family member BAD, 
resulting in its inactivation. No direct binding between E7 and PKB has been 
detected and it is thought that E7 stimulates PKB signalling cascades either by 
decreasing PKB de-phosphorylation by PP2A (Pirn et al, 2005) or in a manner 
dependent on pRB inactivation (Menges et al, 2006).
Centrosome Amplification
Genetic abnormalities are essential hallmarks of cancer cells (Vogelstein & Kinzler,
2004). Genomic instability is a characteristic of HPV-induced malignancies as well 
as many other cancer types (Lengauer et al, 1998). W hether chromosome 
amplification is an essential cause or a consequence of such malignancies remains to 
be clarified. One mechanism that can result in genomic instability is the presence of 
abnormal centrosome numbers at the onset of mitosis. Centrosomes are the major 
organising centres of the microtubule network, which is important in sustaining 
cell morphology, intracellular transport, cellular polarity and chromosome 
segregation (Fukasawa, 2002). A normal centrosome cycle involves the doubling of 
the mother centrosome, followed by maturation, separation and orientation into
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the two poles of a dividing cell (Meraldi & Nigg, 2002). Abnormal centrosome 
numbers result in unequal division of chromosomes in mitosis. Throughout the cell 
cycle multiple proteins are involved in the centrosome cycle thus linking both 
cycles together. These include various protein kinases such as CDK2/cyclin E /A  in 
centriole duplication; Aurora A and Polo-like kinases (Plk) in centrosome 
maturation; and CDKl/cyclinB in centrosome separation and proteolytic 
complexes, such as the Skp, Cullin and F-box complex (SCF) (Nakayama et al, 
2000). The actual substrates of these proteins and their influence on the 
centrosome cycle remain to be elucidated, but deregulated expression of key 
proteins can result in amplified centrosome numbers.
High risk E6 and E7 proteins are both associated with genomic instability 
(Duensing & Munger, 2002b), although the underlying mechanism is uncertain. 
Both E6 and E7 can separately induce mitotic abnormalities when stably expressed 
in cultured cell lines or in cells derived from transgenic mice (Duensing & Munger, 
2002a; Patel et al, 2004; Schaeffer et al, 2004). Further dissection of the role of each 
protein showed that when each protein is transiently expressed, only E7 results in 
immediate chromosomal abnormalities (Duensing et al, 2001a; Duensing et al, 
2000). This suggests that E7 has a direct effect in inducing centrosomal 
abnormalities, while the effects induced by E6 might be an indirect consequence of 
the abrogation of p53 function (Shinmura et al, 2007; Thompson et al, 1997)
Cells expressing HPV-16 E7 appear to develop abnormal centrosome numbers 
before progressing to malignancy (Duensing et al, 2001a). The exact mechanism by 
which E7 causes this and the protein domains required remain to be clarified.
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Unexpectedly, the role of pRB inactivation in centrosome over-duplication (Lentini 
et al, 2006; Meraldi et al, 1999) has not been linked to E7’s activity (Duensing & 
Munger, 2003). E7, therefore, seems to function by directly abrogating the cellular 
machinery involved in centrosome duplication instead of its being an indirect 
consequence of inducing cellular proliferation. In addition, E7 upregulates 
CDK2/cyclin E activity (see above) which is important in licensing for centrosome 
duplication (Hinchcliffe & Sluder, 2001). A series of studies by S. Duensing has 
shown that inhibitors of RNA polymerase II and CDKs could abrogate HPV-16 
E7-induced centrosome abnormalities but not normal centrosome duplication 
(Duensing et al, 2007; Duensing et al, 2004), suggesting that one way by which E7 
may induce centrosome overduplication by activating CDK activities.
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Thesis Aim
Thesis Aim
The aim of this thesis is to provide a deeper insight on molecular mechanisms that 
control the oncogenecity of the HPV-16 E7 protein. The first part of this thesis 
was based on a screen identifying various interactions between virally encoded 
proteins. We were particularly interested in dissecting the E2-E7 interactions since 
a number of recent publications have identified a transcriptionally-independent 
regulation of E7’s activities by E2. W e therefore look at the interaction between E2 
and E7, dissecting the molecular domains mediating this interaction as well as the 
effects that this interaction has on the activity of each protein. W e also extended 
our analysis to identify cellular proteins that may influence the activities of E7 in 
HPV-induced malignancies, where the expression of E2 is commonly lost. In this 
case, we have investigated the potential role of phosphorylation which we show 
influences the stability of E7. Finally, we provide evidence that both E2 and E7 can 
interact with Mdm2, a cellular oncoprotein, which results in modulating the 
activities of E2 and E7 as well as Mdm2 itself.
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Results
Cross-talk between HPV-16 E2 and E7 
E2 and E7 bind in vitro
A previous screen for potential interactions between different HPV proteins 
identified binding between HPV-16 E2 and E7 (Sterlinko Grm, 2005). In this study 
we aimed to characterise this interaction further and to dissect its biological 
functions. First, to confirm the interaction between E2 and E7, we performed a 
number of GST pull-down assays using bacterially expressed GST-tagged proteins 
immobilised on glutathione agarose, which were incubated with in vitro translated 
radiolabelled HPV-16 E2. All binding assays were performed for 1 hr on ice, and 
the reactions were extensively washed with a detergent-containing buffer. As 
shown in Figure 6a, HPV-16 E2 bound strongly to the GST-16E1 positive control 
as well as to GST-16E7. No interaction was detected with GST alone. To 
investigate whether E7 could also pull down E2 expressed in vivo, GST-16E7 was 
incubated with an extract from U 20S cells that had been transiently transfected 
with a 16E2 expression plasmid. As can be seen from Figure 6b (bottom panel), 
GST-16E7 retained significant amounts of 16E2 from the cell extract. In addition, 
using a CaSKi cell extract as a source of E7 protein, significant binding was 
detected with a GST-16E2 fusion protein (Figure 6b, upper panel). Overall, these 
results provide evidence that HPV-16 E2 and E7 can bind in vitro.
The in vitro interaction between E2 and E7 shown above might be direct, or 
mediated through other unknown proteins present in the reticulocyte lysate or in 
the cell extracts. To investigate this, we performed a direct binding assay in which
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Figure 6. E2 and E7 interact in vitro.
a) HPV-16 E2 was in z>z>ro-translated and radiolabelled in reticulocyte lysate and 
incubated with GST, GST-16E7 and GST-16E1. The 50% input of E2 (T T  E2) is 
shown and bound proteins were assessed using autoradiography (bottom  panel) and 
the input GST-fusion proteins were visualised by staining the gels using coomassie 
blue (upper panel), b) Extracts from U 2 OS cells expressing 16E2 and CaSKi cells 
expressing 16E7 were incubated with GST-16E7 and -16E2, respectively. Bound 
proteins were analysed by W estern blotting using anti-E2 polyclonal (bottom  panel) 
and anti-E7 monoclonal antibodies (upper panel), c) A direct binding assay was 
performed using GST-16E2 incubated with purified His-tagged 16E7. G ST  alone 
and G ST-TBP were used as negative and positive controls, respectively. Bound 
proteins were analysed by W estern blotting using anti-E7 monoclonal antibodies 
(bottom panel) and G ST protein inputs were visualised by staining the membrane 
using Ponceau stain (upper panel), d) A comparison of E2 and E7 derived from 
different HPV types. G ST-tagged HPV -11 and -16 E2 proteins were incubated with 
in z/^ro-translated radiolabelled H PV -11 and -16 E7 proteins respectively and bound 
proteins assessed by SDS-PAGE and autoradiography. 50% of the total input 
protein is also shown and the lower panel shows the input G ST fusion proteins; (*) 
denotes full-length fusion proteins.
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both proteins were expressed and purified from bacteria. Soluble, purified His- 
tagged 16E7 was incubated with purified GST-16E2 immobilised on glutathione 
agarose as well as with GST-TBP as a positive control and GST alone as a 
negative control. After 1 hr of incubation at 4°C the resin was extensively washed 
and the amount of E7 retained was then detected by W estern blotting using an 
anti-E7 monoclonal antibody. The results, shown in Figure 6c, demonstrate that 
E7 binds E2 directly and that this interaction is comparable to the interaction 
between E7 and TBP. No interaction was seen between E7 and GST alone.,
Having found that HPV-16E2 and HPV-16E7 could interact directly, we then 
wanted to assess whether this ability was conserved between low- and high- risk 
HPV types. To do this we performed binding assays between the respective E2 and 
E7 proteins derived from HPV-11 and HPV-16. As can be seen in Figure 6d, HPV- 
16 E7 binds to HPV-16 E2 with significantly higher efficiency than that seen 
between HPV-11 E2 and E7, suggesting that the E2/E7 interaction is stronger for 
the high-risk HPV type.
Mapping the site of interaction between HPV-16 E2 and E7
W e then proceeded to map the sites of interaction between HPV-16 E2 and E7. 
The N- and C- terminal halves of E2 (as indicated in Figure 7a) were first in vitro- 
translated and incubated with GST-16E7 bound to agarose. After extensive 
washing, the bound proteins were analysed by SDS-PAGE and autoradiography. 
Figure 7b shows that E7 binds preferentially to the C-terminal half of E2. To 
further map the site of interaction, a series of truncations along the C-terminal 
region of E2 were expressed as GST fusion proteins, these were purified and tested
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for their ability to bind in wfro-translated E7. As can be seen from Figure 7c, E7 
only interacts with those E2 proteins that retain an intact hinge region, thereby 
mapping the site of E7 interaction to a region spanning amino acid residues 202- 
249 of E2, although a role for additional amino acid residues extending to position 
306 cannot be excluded.
Then we performed a similar mutational analysis to map the site of interaction of 
E2 on the E7 protein. As can be seen from Figure 7d, in z>z£ro-translated E2 binds 
preferentially to the GST-tagged C-terminal half of E7. Using a series of deletion 
mutants of E7 (Massimi et al, 1997) translated in vitro, it can be seen that the E7 
mutant lacking residues 79-83 (A4) is defective in its ability to bind GST-tagged 
E2 (Figure 7e). In contrast, the other three mutants within the zinc-binding 
domain of E7 still retain the ability to bind E2.
HPV-16 E2 and E7 in te rac t in  vivo
Having shown that E2 and E7 can interact in vitro, we then proceeded to 
investigate whether we could detect the interaction in vivo. U 20S cells were co­
transfected with HA-tagged 16E7 and un-tagged 16E2, and after 24 hrs cell 
extracts were incubated with anti-HA antibody cross-linked to agarose beads 
(Sigma). After extensive washing, the precipitated proteins were analysed by SDS- 
PAGE and W estern blotting using a polyclonal antibody against 16E2 (Massimi et 
al, 1999). As shown in Figure 8, E2 co-immunoprecipitates with E7, but it is not 
precipitated by the anti-HA antibody if E7 is absent. These results demonstrate 
that E2 and E7 can form a complex in vivo.
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Figure 8. E2 and E7 interact in vivo.
U 2 OS cell extracts expressing 16E2 alone or with HA-16E7 were incubated 
with anti-HA linked to agarose beads and the precipitated proteins were 
detected by W estern blotting using anti-E2 or anti-HA antibodies. 15% of each 
cell extract used for the precipitation was included as inputs. T he arrow  
indicates IgG  light chain, the (*) indicates precipitated proteins.
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HPV-16 E2 increases the stability o f HPV-16 E7
Upon the co-expression of E2 and E7 in U 20S cells we consistently observed that 
E7 levels were increased in the presence of E2, compared with expression of E7 
alone. As shown in Figure 9a (lanes 2, 3 &7), when expressed alone E7 is weakly 
detectable in either the soluble or insoluble fractions of the cellular extract (see 
materials and methods), compared with the expression of (3-gal used as a marker of 
transfection efficiency. However, in the presence of E2 the levels of E7 increase 
markedly (Figure 9a, lanes 4, 5, 8&9). To investigate whether this increase in E7 
levels in the presence of E2 was due to the interaction between the two proteins, 
we repeated the assay and included two mutants of E7 within the zinc-binding 
finger. The results obtained are shown in Figure 9b, where it can be seen that the 
mutant of E7 (A4), that is defective for binding E2, is unaffected by the presence of 
E2; whilst the A3 mutant of E7, which retains E2 binding activity, is stabilised by 
E2 in a manner similar to that seen with wild-type E7.
W e were then interested in investigating the effects of E2 on E7 protein expressed 
endogenously in CaSKi cells. Therefore, CaSKi cells were transfected with E2 and 
the protein levels of E7 in a total cell extract were analysed by W estern blotting 
using antibodies against E7 and actin as a loading control. As demonstrated in 
Figure 10a, the protein levels of E7 are markedly increased in the presence of E2. 
This is independent of E7’s mRNA levels as tested by semi-quantitative RT-PCR 
on cells transfected in a parallel experiment (Figure 10b). To test whether the 
increase in the levels of E7 was due to an increase in its half-life, CaSKi cells were 
transfected with E2 and 24 hrs later, cycloheximide was added to block protein 
synthesis. Cell extracts were then made at different time points and E7 expression 
was analysed by W estern blotting. As can be seen from Figure 10c, the levels of E7
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alone are significantly decreased between 15 and SO minutes into the chase, when 
compared with the levels of actin which is used as a loading control of cell extracts. 
In contrast, in the presence of E2, the initial level of E7 is approximately two-fold 
higher, and this remains constant for much longer and can still be detected up to 2 
hrs into the chase (Figure lOd). Similar results were also obtained using transient 
transfection in U 20S cells, which again was independent of any effects on E7 
mRNA levels (Figure lOe). Taken together, these studies demonstrate that E2 
increases the stability of the E7 protein.
E2 relocalises E7 to the insoluble fraction
In Figure 9a, E7 appears highly soluble and upon the expression of E2 it can also 
be detected in the insoluble fraction. This could be due to an increase in E7 levels 
in the presence of E2, or that E2 can specifically relocalise E7 to the insoluble 
fraction of the cell, which has been previously shown to include chromatin-bound 
E2 and core histones as markers of the chromatin (Donaldson et al, 2007; Kurg et 
al, 2005). To investigate this, we performed a series of assays to investigate the 
effects of E2 on the solubility of E7. To do this, U 20S cells were transfected in 
duplicates with either E2 or E7 separately, or with a combination of E2 and E7. 
One set of transfected cells were left untreated, while the other was pre-treated 
with a Triton-based pre-permeabilisation buffer prior to cell extraction. In both 
cases, cell extracts were separated into soluble and insoluble fractions and protein 
levels were detected by W estern blot using specific antibodies against E2, E7 and 
(3-gal as a marker for transfection efficiency. As shown in Figure 1 la, E7 by itself is 
localised almost entirely within the soluble fraction of the cell and is completely
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Figure 9. 16E7 protein levels are stabilised when co-expressed w ith 16E2 in 
U 2 0 S  cells.
a) Different amounts of H A-tagged E7 were transfected with or w ithout E2. 
W estern blots of soluble and insoluble fractions of the cellular extracts expressing 
different combinations of E2 and E7 were probed using polyclonal anti-E2 and 
monoclonal anti-HA antibodies. The expression of P-gal was used as a control of 
transfection efficiency, b) Cells grow n in 6-well dishes were transfected with 
plasmids expressing wild-type (w.t) HA-tagged 16E7 and the A3 and A4 m utants 
of HA-16E7 with or w ithout Ec2. Total cell extracts were analysed by W estern  blot 
using anti-HA or anti-P-gal antibodies.
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Figure 10. Increase in the stability and half-life o f  E7 in the presence o f  E2.
CaSKi cells were plated at 80000 cells per well in 6-well dishes and transfected with 
3pg of empty plasmid or plasmid expressing 16E2. 24h later, the levels of E7 were 
analysed in total cell extracts by (a) W estern blot using monoclonal anti-E7 and an ti-a - 
actin antibodies or by (b) semi-quantitative R T-PC R  using specific prim ers to amplify 
E2, E7 and actin. -R T  controls were included as a control of RNA purity, c&d) CaSKi 
cells transfected using Lipofectamine2000 with empty plasmid (c) or plasmid expressing 
16E2 (d) were treated at different times with cycloheximide (ChX) in DM SO or w ith 
DMSO alone for 120 minutes. Cells were harvested at different times (0, 15, 30, 60 and 
120 minutes) after cycloheximide treatm ent and the protein levels o f E7 were analysed 
by W estern blot using monoclonal antibodies against 16E7 or a-actin . T he intensities 
o f the bands were measured using Adobe Photoshop and the mean results from three 
independent experiments are shown together with standard deviations (c&d lower 
panels), (e) H alf life of E7 over-expressed in U 20S  in the presence or absence o f E2. 
Cells plated in 6 well dishes were transfected with 2pg o f E7 alone or w ith l|Jg  o f E2 
expression plasmids and processed as in (c&d). p-gal was used as a transfection control 
and monoclonal anti-HA were used to visualise HA-tagged E7.
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F igure  11. E7 is re localised  to  th e  insoluble frac tio n  o f  th e  cell in  th e  p resence  
o f  E2.
a) U 20S  cells were transfected in duplicates with plasmids expressing either E2 or 
E7 alone or in combination along with a plasmid expressing P-gal as a control for 
transfection efficiency. One set of transfected cells was left untreated, while the other 
was treated with a pre-permeabilisation buffer for 7 minutes. In all cases, cells were 
then harvested and extracted with E l A extraction buffer, and the soluble and 
insoluble fractions of the cell were analysed by W estern  blotting using antibodies 
against E 2, E7 or P-gal. b) U 2 OS cells grown on coverslips were transfected in a 
parallel experiment as above. After treatm ent with the pre-perm eabilisation buffer, 
cells were fixed with PFA and analysed by immunofluorescence using rabbit anti-E2 
(green) and mouse anti-E7 (red) antibodies. The scale bar shown (10 pm) is shown 
at the lower left side of the merged images.
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lost when cells are pre-permeabilised. On the other hand, E2 appears in both the 
soluble and insoluble fractions and is resistant to the pre-permeabilisation 
treatment. In a previous work by McPhillips and colleagues the protein expression 
of HPV-16 E2 was lost upon treatment with extraction buffer (McPhillips et al, 
2006). The difference between these results and ours could be due to the use of a 
different pre-extraction procedure and variation in the expression levels of E2. In 
those cells expressing both E2 and E7, there is an overall increase in the levels of 
E7 expression (consistent with results in Figure 9a). However, the bulk of this 
increase is in the insoluble fraction and, most importantly, the E7 protein in this 
fraction also becomes resistant to the pre-permeabilisation treatment. In contrast, 
the E7 protein that remains in the soluble fraction is still largely removed by the 
pre-permeabilisation treatment.
This analysis was then repeated and the pattern of E7 and E2 expression was 
monitored by immunofluorescence. The results obtained are shown in Figure l ib. 
W hilst E2 and E7 are both expressed in the nucleus, pre-permeabilisation 
completely abolishes E7 expression, whereas E2 can still be detected in the 
nucleus. In contrast, when E2 and E7 are co-expressed, there is a strong retention 
of E7 following the pre-permeabilisation treatment. Taken together, these results 
indicate that E2 can redirect E7 to an insoluble compartment within the nucleus. 
The possible biological consequence of this is discussed below.
HPV-16 E2 inhibits E7 induced transformation
Having shown a direct interaction between E2 and E7, we were then interested to 
examine whether this interaction, which results in increased stability and
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relocalisation of E7, affects any of its major oncogenic activities. Previous studies 
have shown that the over-expression of the E2 protein resulted in cell growth 
arrest in cell lines containing integrated HPV DNA, due to suppression of E6 and 
E7 gene transcription (Dowhanick et al, 1995; Francis et al, 2000). However, we 
were interested in whether E2 had any direct effects upon the transformation 
activity of E7 in the absence of an E2-responsive promoter. To do this, we 
performed a transformation assay using primary Baby Rat Kidney (BRK) cells 
transfected with HPV-16 E7 and EJ-Ras, with or without HPV-16 E2 (Massimi et 
al, 1997). Parallel transfections using Adenovirus E l a and EJ-Ras were performed 
for comparison. After two weeks of selection the cells were fixed, stained and the 
number of colonies was counted. The results obtained are shown in Figure 12a, 
where it can be seen that HPV-16 E2 is a potent inhibitor of E7 transforming 
activity. This effect of E2 appears to be specific since, in contrast, E2 has no effect 
on the transforming activity of Adenovirus E la  (Figure 12b). To verify that the 
expression of E7 from the pJ4Q plasmid was not inhibited by the E2 expression 
plasmid, we analysed the level of E7 gene expression 24 hrs after transfection into 
BRK cells by semi-quantitative RT-PCR analysis. Figure 12c shows that E2 does 
not inhibit E7 expression in this assay system, suggesting that E2 suppression of 
E7-induced transformation is at the post-transcriptional level.
Since the level of E7 protein expressed from the pj4Q  plasmid is very low and 
cannot be detected by W estern blotting, we sought to confirm the above 
observations using E7 expressed at higher levels from the pcDNA3 plasmid. Using 
the procedures described above for the BRK transformation assay, we optimised 
the expression levels of pcDNA.E7 plus EJ-Ra.? in order to achieve a comparable 
transforming activity to that obtained with pj4Q.E7 and EJ-Ras (Figure 12d). The
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F igure  12. T ran sfo rm atio n  ac tiv ity  o f  E7 is in h ib ited  in  th e  p resence  o f  E2.
Prim ary BRK cells from 9-day-old W istar rats were transfected with 6pg of 
either a) p J tQ  HPV-16 E7 or b) PCE Adenovirus E la  together with Ras as a co­
operating oncogene and pcDNA carrying a selectable marker. Cells were 
maintained in 200 |ig /m l-G 418 containing medium for 2 weeks, and then fixed 
and stained and the colony numbers were counted (as shown in the top panel). 
The chart shows the mean of 3 independent experiments, and erro r lines indicate 
standard deviations, c) BRK cells, treated as in (a), were transiently  transfected 
with 6pg of p j4Q  plasmid expressing E7 and increasing am ounts of E2, along 
with a G FP  expressing plasmid as a control for transfection efficiency, ip g  of 
total cell RNA was reverse transcribed and the expression of E2, E7 and G F P  
was analysed by semi-quantitative PCR using specific primers.
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Figure  12. T ran sfo rm a tio n  ac tiv ity  o f  E7 is inh ib ited  in th e  p resence o f  E2.
(,cont.)
d) BRK cells were transfected with 2jUg of plasmid expressing E la  and pcDNA or 
3pg of pcDNA 16E7 along with Ras expression plasmid and increasing amounts of 
either untagged 16E2 (cmv 16E2) or GEP-tagged 16E2 as indicated. Cells were 
treated and analysed as above, e) W estern blot showing the levels of E7 in U 20S  
cells expressed from the pcDNA plasmid with various amounts of different E2 
expression plasmids, as in (e). P~gal was used as a transfection control and rabbit 
anti-E2 or mouse anti-E7 antibodies were used to test for E 2 and E7 protein levels.
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expression of E2, as well as a GFP-tagged form of E2 (GFP-E2), inhibited 
pcDNA.E7 transformation activity. GFP-E2 had no effect on the transformation 
activity of E l a, confirming that E2 specifically inhibits E7’s transforming activity 
and that this inhibition is not due solely to a general suppression of cellular 
transformation. Furthermore, when the levels of E7 protein were assessed by 
W estern blotting, it was found that E2 did not inhibit E7 expression, instead it 
resulted in an increase in the levels of E7 (Figure 12e) which is consistent with the 
results presented in Figure 9a confirming an increase in the stability of E7 in the 
presence of E2. Overall, this set of experiments provides direct evidence that E2 
inhibits the transforming activity of the E7.
Centrosome abnormalities induced by E7 are inhibited by E2
An additional cancer-associated activity of E7 has been suggested to be its ability 
to induce abnormal centrosome duplication and thereby contribute to the 
development of genomic instability (Duensing & Munger, 2002b). W e therefore 
sought to investigate the effects of E2 upon this activity of E7. To do this, 
centrosome numbers were monitored in U 2OS cells transiently transfected with an 
HA-tagged-HPV-16 E7 expression plasmid, in the presence and absence of an 
HPV-16 E2 expression plasmid. 24 hrs after transfection, cells were treated with 
nocodazole for a further 24 hrs to arrest cells in the G2/M -phase of the cell cycle 
where centrosome duplication would be expected have been completed. Cells were 
then fixed and stained for E2 and E7 using anti-E2 and anti-HA antibodies, 
respectively and for centrosomes using an antibody against the centrosome 
structural protein, y-tubulin. The results obtained are shown in Figure 13. Cells
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expressing E2 alone contained up to two centrosomes per cell, which is the 
characteristic number for cells arrested in G 2/M  (Figure 13a, upper panel). In 
contrast, a significant proportion of the cells expressing E7 contained elevated 
numbers of centrosomes, frequently possessing three or more per cell (Figure 13a, 
middle panel), and these results are consistent with previous publications 
(Duensing et al, 2004; Duensing & Munger, 2003). However, in those cells co­
expressing E2 and E7, there was a reduction in the number of cells harbouring 
aberrant numbers of centrosomes (Figure 13a, lower panel). Figure 13b shows the 
collated results from multiple experiments and confirms the statistically significant 
effects of E2 upon the ability of E7 to induce abnormal centrosome duplication. 
The E7-induced increase in centrosome numbers is also observed in cells that have 
entered mitosis and again this is abolished by the co-expression of HPV-16 E2 
(Figure 13c). These observations indicate that, while E2 does not inhibit the 
normal centrosome duplication cycle of the cell, its expression nonetheless inhibits 
E7-induced centrosome over-duplication, thus providing further evidence of E2’s 
ability to regulate the oncogenic activities of E7 post-transcriptionally.
HPV-16 E2 inhibits E7 mediated degradation o f pRB
Previous studies have suggested that the ability of E7 to induce centrosome 
abnormalities is independent of its ability to target pRB (Duensing & Munger, 
2003). However, pRB targeting by E7 is important for its ability to cooperate with 
EJ-Ras in the transformation of primary BRK cells (Heck et al, 1992) and we were 
therefore interested in investigating the effects of E2 upon E7-induced degradation 
of pRB. To do this, pRB degradation assays were performed in SAOS-2 cells. These 
were transfected with a pRB expression plasmid, together with appropriate
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Figure  13. E ffects o f  E2 on cen trosom e abnorm alities  induced  by E7.
U 2 OS cells grown on coverslips were transiently transfected with HA-tagged 16E7, 
untagged 16E2, or both E2 and E7 expression plasmids. 24 hrs after transfection 
cells were treated with nocodazole for a further 24 hr period to arrest cells in G 2 /M  
phase. Then, cells were fixed with PFA and stained using Hoechst to visualise 
genomic DNA, polyclonal antibodies against E2 or anti-HA. M onoclonal anti-y- 
tubulin was used to visualise centrosomes. a) typical centrosom e num bers in cells 
expressing E2, E7 or E2 with E7. A magnification of the centrosom es is shown on 
the right, b) Statistical analysis of centrosome numbers are shown in the graph 
which represents the results of 3 different assays and a total of approxim ately 150 
cells counted for each transfection along with the standard deviation obtained, c) 
The staining of cells that have entered mitosis processed as for panel (a).
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combinations of untagged HPV-16 E7 and HPV-16 E2 expression plasmids. After 
24 hrs, the levels of pRB protein were ascertained by W estern blotting and the 
results obtained are shown in Figure 14. As can be seen, E7-induced degradation of 
pRB was rescued in the presence of E2. These results demonstrate that E2 can 
inhibit E7-induced degradation of pRB and provide a molecular explanation for the 
ability of E2 to inhibit E7’s transforming activity in BRK cells.
E7 up-regulates E2-dependent transcriptional activation
Having shown that E2 binds and stabilises the E7 protein (Figures 9 and 10), but 
at the same time inhibits its transforming activity (Figure 12), we were next 
interested in investigating the potential effects of E7 upon the functions of E2. 
Since E7 can co-localise with chromatin-bound E2, we aimed to test whether, by 
doing so, E7 can affect E2-mediated transcriptional activation. Previously it was 
shown that E2 binds to its consensus sequence and can activate transcription from 
a promoter containing its DNA binding site (Donaldson et al, 2007). Here, we used 
a Firefly luciferase reporter construct that contains 6 synthetic tandem repeats of 
the E2 DNA-binding site upstream of the luciferase gene. This construct was 
transfected into either U 20S (p53/pRB positive) or SAOS-2 (p53/pRB negative) 
cells, together with GFP-tagged E2 and untagged-E7 expression plasmids, and the 
unrelated Renilla luciferase gene which is used to control transfection efficiency. 24 
hrs after transfection, luciferase activity was measured and results are shown in 
Figure 15a. As can be seen, the transcriptional activation by E2 increases with 
increasing amounts of E7 in both cell lines, meanwhile W estern blot analysis 
shows that the levels of E2 protein remain constant (Figure 15b). These results
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indicate that E7 enhances E2 transcriptional activity in a manner that is 
independent of pRB or p53 activities.
E7 co-localises with E2 on m itotic chromosomes
A recently described chromatin-mediated function of E2 is viral genome 
segregation in mitosis which involves its binding to mitotic chromosomes 
(Skiadopoulos & McBride, 1998). This activity of E2 has been mainly studied using 
E2 protein derived from BPV-1, which was shown to bind to the cellular protein 
Brd-4 on the chromatin (You et al, 2004). Prior to investigating the potential 
effects of E7 upon E2 localisation during mitosis, we sought to examine whether 
HPV-16 E2 could bind to mitotic chromosomes in a similar manner to what has 
been reported for BPV E2. To do this, E2 was over-expressed in U 2OS cells; 48 
hrs later the cells were fixed and E2 was detected using a polyclonal antibody 
against HPV-16 E2. The cells were also stained with Hoechst to visualise cellular 
chromosomes. The cells were not synchronised by drug treatment and 
visualisation of the chromosomal patterns was used to determine the stage of 
mitosis (Scholey et al, 2003) in which the cells were fixed. As can be seen from 
Figure 16a, HPV-16 E2 shows a diffused nuclear staining in interphase cells, and 
during the initial stages of mitosis it is excluded from condensed chromosomes 
(Figure 16b). As the cell enters telophase, E2 localises to mitotic chromosomes 
(Figure 16b, lower panel).
Since both E6 and E7 are known to induce chromosomal segregation defects 
(Duensing et al, 2004), we were then interested to see whether they exert these 
effects by binding directly to the chromosomal arms. Neither E7 nor E6, when
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F igure  14. E2 inh ib its  E 7-m ed iated  deg rad a tio n  o f  pRB.
SAOS-2 cells were transfected with a pRB expression plasmid, along with either 
CMV. 16E2 or PCDNA . 16E7 alone or in combination, as well as a G F P  
expressing plasmid as a control for transfection efficiency. 48 hrs after 
transfection, cells were harvested in E l A buffer, and protein levels analysed by 
W estern blot using antibodies against pRB and G F P.
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F igure 15. E7 enhances th e  tran sc rip tio n a l ac tiv ity  o f  E2.
a) U 2 OS and SAOS-2 cells were transfected with 2 |lg  of G FP-tagged  E2 
expression plasmid (GFPE2), along with increasing amounts of pcDNA.16E7 
as well as a luciferase expression plasmid containing 6X E 2 binding sites and 
Renilla as a control for transfection efficiency. G raphs show the percentage 
activation of the luciferase gene calculated as a mean of three independent 
experiments, b) U 2 OS cells transfected as above were analysed for the levels of 
E2 in the presence of increasing amounts of E7 by W estern  blot using 
polyclonal anti-E2 and monoclonal anti-E7 antibodies.
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F igure  16. T h e  localisa tion  o f  E2, E7 and E6 in  U 2 OS cells.
U 20S  cells grown on cover-slips in 6-well dishes were transfected with 
plasmids expressing 16E2 and /o r HA-tagged 16E7 and 16E6. 48 hrs after 
transfection, cells were fixed and probed with rabbit anti-E2 and mouse anti-HA 
antibodies, followed by FITC-conjugated goat anti-rabbit (green, for E 2) and 
rhodamine-conjugated goat anti-mouse antibodies (red, for E7 and E6). The 
slides were scanned using Leica DMLB fluorescence microscope, a) Interphase 
U 2 OS cells were visualised for separate or co-expression of the E c2 and E7 
proteins, b) Localisation of 16E2, c) 16E7 and d) 16E6 at different stages of 
mitosis. Chromosomes are visualised using Hoechst stain.
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F igure 17. E2 rec ru its  E7, b u t n o t E6, to  m ito tic  chrom osom es a t te lophase .
U^OS cells were processed as described for Figure 7. a) The co-expression of E c2 and 
E7 at different stages of mitosis. Telophase cells were also scanned using confocal 
microscopy (b) where E^ is green, E7 red and the merged image shows clear 
confocality. The same assay was also done using anti-E^ monoclonal antibodies 
(m ono-aE2) together with rabbit anti-HA antibodies to detect E7 (c).
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F igure  17. E2 rec ru its  E7, bu t n o t E6, to  m ito tic  chrom osom es a t te lophase .
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d) The specificity of the antibodies used in (a; left panel) was verified by staining 
telophase cells expressing either HA-tagged E7 alone (upper panel) or E2 alone 
(lower panel) with both rabbit anti-E2 and mouse anti-HA antibodies, e) 
Localisation of E2 and the E7 A4 deletion m utant during telophase. Note 
chromosomal localisation of E2 but chromosomal exclusion of the E7 m utant, f) 
The localisation of the HA-tagged 16E6 protein co-expressed with E2 throughout 
mitosis showing 1 1 0  recruitm ent of E6 onto mitotic chromosomes.
Hoechst 16E2 16E6
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transfected alone, were detected on mitotic chromosomes in any of the stages of 
mitosis; they show instead diffused staining and chromosomal exclusion (Figures 
16 c and d). However, when HA-tagged E7 (stained with monoclonal anti-HA 
antibodies) is co-expressed with E2 (detected using polyclonal anti-E2 antibodies), 
it can clearly be detected on mitotic chromosomes together with E2 at telophase 
(Figure 17a, lower panel). The co-localisation between E2 and E7 was also 
confirmed by scanning with confocal microscopy (Figure 17b). As an additional 
control, E2 was also detected using a previously described monoclonal antibody 
(Hibma et al, 1995) together with a rabbit anti-HA antibody to detect E7 (Figure 
17c) and a similar pattern of expression was observed. To further verify the 
specificity of the antibodies used in the fluorescence experiments, telophase cells 
expressing either E2 or HA-tagged E7 alone were also stained with both rabbit 
anti-E2 and mouse anti-HA antibodies. Figure 17d shows that in the absence of the 
antibody-specific protein, a very low background staining was obtained, indicating 
no cross-reaction between the different antibodies and proteins. To verify that the 
E2-induced re-localisation of E7 onto chromosomes was dependent upon the 
association between E2 and E7, we repeated the assay using the A4 m utant of E7 
which cannot bind to E2. As can be seen from Figure 17e, E2 shows clear co- 
staining with the chromosomes whilst the E7 A4 mutant does not. Finally, the 
specificity of the re-localisation was further confirmed by the inclusion of HA- 
tagged 16E6, which was previously shown to interact with E2 (Grm et al, 2005), 
and where no E2-induced alteration of the pattern of E6 expression was seen 
during mitosis (Figure 17f). These results demonstrate a specific re-localisation of 
the E7 protein onto mitotic chromosomes as a direct result of its interaction with 
E2 during telophase.
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Regulation o f  E7 by Phosphorylation 
The identification o f a P in l binding site on HPV-16 E7
Since the above data had indicated that E7 was post-transcriptionally regulated by 
E2, we were keen to investigate the underlying mechanism. We asked whether it 
might be related to phosphorylation events on E7 having direct effects on protein 
turnover. W e therefore scanned the E7 sequence for the presence of other 
additional regulatory sequences; in addition to the previously described CKII 
phosphorylation site; we could not identify any strong matches to kinase 
phosphorylation sites but we could detect a potential binding site for the prolyl 
isomerase P inl. P inl regulates the activity of numerous key cell cycle regulatory 
proteins such as p53, c-myc and cyclin E. It binds its targets by recognising proline 
residues preceded by a phosphorylated serine or threonine residue (pSer/Thr-Pro). 
A potential Pinl binding motif was identified at amino acid residues 5 and 6 in the 
CRl domain of HPV-16 E7. To verify the binding between E7 and P inl, we 
conducted an in vitro binding assay in which, in vitro translated 16E7 was incubated 
with GST-Pinl. As can be seen in Figure 18a, in vitro translated E7 bound to GST- 
P inl but not to GST alone. Having shown an in vitro binding between E7 and 
Pin 1, we then tested whether the expression level of E7 in vivo is affected in the 
presence of P inl. To do so, HA-tagged E7 expression plasmid was co-expressed in 
U 2OS cells together with an HA-tagged Pinl expression plasmid. Figure 18b 
shows that the level of E7 is increased in the presence of Pinl. To show that the 
effect of Pinl on E7 expression is dependent on the phosphorylation of E7, we 
additionally over-expressed the protein phosphatase 2A (PP2A) subunit which was
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Figure 18. Pinl binds E7 and increases its levels in vivo.
a) E7 and P inl can bind in vitro. G ST-tagged P in l, as well as G ST-alone as a 
negative control, were incubated with in vitro translated and radiolabelled E7 for 
ih r  on ice. Following extensive washing with a detergent containing buffer, the 
amount of binding was detected using SDS-PAGE and autoradiography, b) P in l 
stabilises the levels of E7 in vivo. U 2 OS cells were transfected using HA-tagged 
E7, along with HA-tagged P inl and PP2A expression plasmids. 24 hrs after 
transfection, protein levels were analysed by W estern  blot using anti-HA 
antibodies and P-gal as a transfection control, c) P in l does not perturb  pRB 
degradation mediated by E7. SAOS-2 cells were transfected using pRB 
expression plasmids, as well as pcDNA.16E7, H A -Pinl, or both E7 and P inl 
expression plasmids. Protein levels were analysed using W estern blot 24 hrs 
after transfection using antibodies against pRB or G FP  as a transfection control.
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shown previously to interact with HPV-16 E7 (Pirn et al, 2005) as well as with a 
number of other virally encoded proteins (Van Hoof & Goris, 2004). W e speculated 
that if the activity of PP2A can result in the reduction of E7 phosphorylation then 
the expression of Pin 1 will no longer affect E7 levels. Indeed, the co-expression of 
P inl and E7 in the presence of PP2A diminished the increase in E7’s levels (Figure 
18b) thus indicating that the phosphorylation of E7 is important for its 
stabilisation by P inl. Having shown previously that E7 when stabilised by E2 loses 
some of its functional activities (Figures 12, 13 and 14), we were interested to test 
whether the stabilisation of E7 induced by P in l affects its ability to degrade pRB. 
Using an in vivo degradation assay of pRB in SAOS-2 cells, we observed that the 
expression of Pinl by itself does not affect pRB levels, and when co-expressed with 
E7 it does not impair the E7-mediated degradation of pRB (Figure 18c). Overall, 
these results provide new evidence that Pinl binds to E7 and increases E7 protein 
levels, however, it does not appear impede E7-mediated degradation of pRB.
Modulation o f E7 levels by phosphorylation
Having shown above that P in l, whose interaction with various proteins is 
determined by their phosphorylation, binds to and affects the stability of E7, we 
speculated whether phosphorylation by itself might play a role in regulating E7 
levels. To test this, E7 was transiently expressed in the presence of a wild-type 
PP2A subunit, a dominant negative mutant of PP2A (PP2A-DN), and okadaic acid 
(OA), which is an inhibitor of endogenous PP2A activities. Figure 19a shows that 
the levels of E7 are reduced upon the expression of PP2A. In contrast, higher E7 
levels were detected in the presence of either PP2A-DN or OA. This indicates that
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inhibiting the dephosphorylation of E7, and thus increasing its phosphorylation, 
results in its increased levels and also suggests that phosphorylation may modulate 
the stability of E7. Until now, two phosphorylation sites have been identified on E7 
including the CKII phosphorylation site (residues 31 and 32) (Firzlaff et al, 1989) 
and serine 71 which is phosphorylated by an unknown kinase (Massimi & Banks, 
2000). To examine whether E7 mutants harbouring substitutions in the CKII 
recognition consensus (E7 31/32) or in serine 71 (E7 S7l) are resistant to OA 
treatment, we treated U 20S cells transiently expressing E7 31/32 or E7 S71 with 
OA as before, and monitored protein levels using W estern blotting. As can be seen 
from Figure 19b, both mutants of E7 are stabilised in the presence of OA in a 
similar fashion to the wild-type E7 protein. This suggests that additional 
phosphorylation sites on E7 are important for controlling its stability.
W e then sought to identify potential kinases that would alter the stability of E7. 
Since phosphorylation plays a potential role in regulating E7 levels, we reasoned 
that inhibiting the activity of a stabilising kinase might lead to a reduction in E7 
levels. To test this, cells expressing E7 were treated with a number of kinase 
inhibitors and the changes in E7 levels were assessed using W estern blotting. The 
various inhibitors used (Table 3) include the cell cycle inhibitors, aphidicolin and 
nocodazole, plus inhibitors of Aurora A kinase and PIK3: none of these greatly 
affected the expression levels of E7 (Figure 19c). In contrast, treating cells with the 
CDK inhibitor, roscovitine, drastically reduced the expression levels of E7 
suggesting that the activity of CDK can influence the stability of E7.
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F igure  19. R egu lation  o f  E7 s tab ility  by phosphory la tion .
a) HA-tagged E7 was expressed in U 20S  cells along with HA-tagged PP2A or a 
PP2A dominant negative (DN) mutant. Cells expressing E7 alone were also 
treated with okadaic acid (OA) for 5hrs prior to harvest. The W estern blot 
analysis shows the levels of HA-tagged proteins using monoclonal anti-HA 
antibodies and P-gal is shown as a transfection control, b) T he levels of 
expression of the untagged CKII m utant (E7 31/32) and serine 71 m utant (E7 
S7l) of E7 in the presence of OA compared with untagged wild-type E7 analysed 
by W estern blot using monoclonal antibodies against E7. c) U 20S  cells 
expressing HA-tagged E7 were treated using various kinase and cell cycle 
inhibitors (see table 3) for 8 hrs. Cells were then harvested and the levels of E7 
were analysed by W estern blot using anti-HA antibodies.
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Table 3: Various Inhibitors used
Inhibitor
name Aphidicolin Nocodazole Roscovitine Apigenin LY294002
Aurora kinase 
II inhibitor
Targeted
molecule
DNA
polymerase Microtubule CDK 1/2 CKII PIK3 Aurora II
Short
Name aph noc ros api PIK3i Aurll
W e extended our analyses to also investigate whether CKII phosphorylation of E7 
can modulate its stability. To do this, we included in our assays the specific CKII 
inhibitor apigenin. Figure 20a shows that inhibiting the activities of both CDK2 
and CKII using roscovitine and apigenin, respectively, results in reduced levels of 
E7. This reduction in the levels of E7 in the presence of CDK2 and CKII inhibitors 
can be rescued upon the addition of proteasome inhibitors (Figure 20b) indicating 
that enhanced degradation of E7 is mediated by the proteasome. To confirm the 
specificity of the kinase inhibitors used, we treated cells expressing the E7 31/32 
mutant with apigenin and roscovitine. As can be seen in Figure 20c, the levels of 
E7 31/32 are unaffected by apigenin treatment, consistent with its not being 
phosphorylated by CKII, whilst the addition of roscovitine reduces its levels in a 
manner similar to that seen with the wild-type protein. Overall, these results 
suggest that phosphorylation of E7 plays an important role in controlling its 
stability, and that inhibiting the potential phosphorylation of E7 by CDK2 or CKII 
results in enhanced proteasome-mediated degradation of E7.
E7 is phosphorylated in vitro by CDK2
The above studies indicate that E7 may be a potential substrate for 
phosphorylation by CDK2. To test this, we performed an in vitro phosphorylation 
assay by incubating GST-16E7 with purified CDK2, in the presence of
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radiolabelled ATP (32P-ATP), at 30°C for 20 minutes. The amount of ATP 
incorporation was monitored by auto-radiography and the results are shown in 
Figure 21a. It can be seen that E7 is significantly phosphorylated by CDK2, mostly 
on its N-terminal half, compared with the negative control of GST alone.
HPV-16E7 has been shown to form part of CDK2-containing complexes in vivo 
(He et al, 2003) and our results indicate that CDK2 can potentially phosphorylate 
E7. Since inhibiting CDK2 activity reduces the expression levels of E7 (Figure 
19c), ecptopically expressing CDK2 should lead to enhanced levels of E7. To test 
this, we transiently co-expressed E7 with CDK2 or cyclin E in U 20S cells and 
analysed E7 protein levels by W estern blotting. Figure 2 lb shows that E7 protein 
levels are greatly increased in the presence of CDK2 or cyclin E, which confirms 
that the activity of CDK2, and its potential phosphorylation of E7, plays an 
important role in regulating the stability of E7. In addition, to further confirm 
these results, we monitored the levels of E7 during the cell cycle where the 
activities of different CDK complexes vary. Cells expressing E7 were arrested in 
G l/S-phase by treatment with aphidicolin for 24 hrs. Following release, the cells 
were harvested at different points of the cell cycle. As can be seen in Figure 21c, 
the levels of E7 are significantly higher during the G 1 / S-phase of the cell cycle 
(confirmed in the FACS analysis), and this correlates with a higher activity of 
CDK2/cyclin E complex. This suggests that the activity of endogenous CDK2 can 
affect the levels of E7 protein along the cell cycle.
To test whether the 5th residue of HPV-16 E7 is phosphorylated by CDK2, we 
made a point mutation substituting the 5th amino acid of E7 with an alanine (E7 
T5A) and made a double mutation of both threonines which flank the 6th proline to 
alanines (E7 T5/7A). When expressed as a GST-fusion protein, both E7 T5A and
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Figure  20. T h e  ac tiv ities  o f  b o th  CKII and CDK2 are  im p o rtan t fo r re g u la tin g  
p ro teasom e m ediated  d eg rad a tio n  o f  E7.
a) CKII inhibitors can also affect the stability of E7. U 20S  cells expressing 
pcDNA. 16E7 were treated as in 14 (c) along with the inclusion of the CKII inhibitor, 
apigenin. (api) E7 was detected by W estern blot using anti-E7 monoclonal 
antibodies, b) U 20S  cells expressing pcDNA. 16E7 were treated for 3 hrs with 
CDK2 (ros) or CKII (api) inhibitors with or w ithout the addition of the proteasom e 
inhibitor epoxomycin. c) The CKII m utant E7, E7 31/32, is resistant to treatm ent 
with apigenin but not to treatm ent with roscovitine. Cells expressing E7 31 /  32 
were treated for 3 hrs with OA, api or ros, and E7 was detected by W estern  blot 
using anti-E7 antibodies.
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Figure 21. E7 is phosphorylated by CDK2 in vitro and the ectopic 
expression of CDK2 or cyclin E affects its levels in vivo.
a) Bacterially purified GST-16E7, as well as the N- and C-term inal halves of E7, 
were incubated with purified CDK2 along with A T P -32P at 30°C for 20 minutes. 
After extensive washing with the kinase buffer, the am ount o f A TP 
incorporation was analysed using SDS-PAGE and autoradiography. T he bottom  
panel shows the coomassie stain of the input GSTs. b) T he over-expression of 
CDK2 or cyclin E dramatically increases the expression level of E7. U 2 OS cells 
were transfected with pcDNA. 16E7 expression plasmid, along with HA-tagged 
CDK2 or a cyclin E expression plasmid. Protein levels were detected by W estern  
blot using anti-E7 and anti-HA antibodies, c) The expression of E7 at different 
stages of the cell cycle the cell cycle. U 2 OS cells expressing H A-tagged E7 were 
treated with aphidicolin for 24 hrs, and then released and harvested at different 
points in the cell cycle. The levels of E7 expression were analysed by W estern  
blot using anti-HA antibodies. The FACS analyses are also shown to indicate the 
stage of the cell cycle at which the E7 protein levels were analysed.
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F igure  22. T h e  T5A  and th e  T 5 /7 A  m u tan ts  o f  E7 are  s till p h o sp h o ry la ted  
by CDK2 in  vitro.
a) In vitro phosphorylation assay using G ST-tagged m utants of E7 was 
conducted as in figure 16a. b) CDK upregulates the expression level of the T5A 
and T 5/7A  m utants of E7. Protein levels were detected by W estern  blot using 
antibodies against 16E7, HA or (3-gal which was used as a transfection control, c) 
The assay was carried out as in (b) using the E7 S71 or E7 S71T5/7A  m utants of 
E7.
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E7 T5/7A  were still phosphorylated by CDK2 in vitro (Figure 22a). As expected, 
both mutants of E7 were also stabilised by CDK2 when expressed in vivo (Figure 
22b), indicating the existence of additional sites for CDK2 phosphorylation that are 
required for the stabilisation of E7. In addition, we were interested in testing the 
effects of CDK2 expression on the serine 71 mutation of E7 (E7 S7l) which was 
shown to be phosphorylated by an unknown kinase in a cell cycle dependent 
manner (Massimi & Banks, 2000). Figure 22c shows that the expression levels of 
E7 S71, as well as a triple mutant containing substitutions in residues 5,7 and 71 
(E7 S71T5/7A), are increased in the presence of CDK2. Overall, these results 
suggest that CDK2-mediated phosphorylation and stabilisation requires sites 
additional to threonines 5 and 7 and serine 71 on E7.
A potential role for Mdm2 in regulating HPV protein function 
Mdm2 binds to HPV-16 E2 and E7
The proteasome plays an important role in influencing the stability of both E2 and 
E7 (Bellanger et al, 2001; Reinstein et al, 2000) as well as mediating many of E6 
and E7’s activities (Boyer et al, 1996; Gardiol et al, 1999; Matlashewski et al, 1987). 
In addition, E2 was shown to modulate the proteasome-mediated degradation of 
some of the cellular targets of E6 (Grm et al, 2005) and E7 (this study). We 
therefore considered to examine whether E2 can interact with the proteasome 
machinery, and in particular, with Mdm2 which seems a good candidate as it 
enhances the degradation of both p53 and pRb (Ying & Xiao, 2006), the main 
cellular targets of E6 and E7, respectively. To address this, we initially sought to
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examine whether E2 can interact with Mdm2. Using an in vitro binding assay, 
bacterially expressed GST-fusion proteins were was incubated with in vitro 
translated and radiolabelled Mdm2. Figure 23 shows that Mdm2 can bind to GST- 
16E2 albeit less strongly than it binds to GST-p53; no binding is seen with GST 
alone. Unexpectedly, we also detected binding between Mdm2 and GST-16E7; 
although this was weaker than the E2-Mdm2 interaction, it was, nonetheless, 
significant. These results indicate a possible interplay between HPV proteins and 
Mdm2.
Mdm2 enhances proteasome mediated degradation o f E7
Since Mdm2 mediates the degradation of a number of its cellular targets, we were 
first interested in testing the protein levels of E2 and E7 in the presence of Mdm2. 
To address this, U 2OS cells were transfected with E2 or E7 expression plasmids, 
along with Mdm2 and p-gal as a transfection control. The expression levels of E2 
and E7 were then analysed by W estern blot. As can be seen in Figures 24a and 
27a, increasing the expression of Mdm2 results in a decreased abundance of the E7 
protein, while the levels of E2 remain largely unchanged with respect to the |3-gal 
loading control. In the case of E7, its reduced level in the presence of Mdm2 was 
reversed upon the addition of proteasome inhibitors (Figure 24a), suggesting that 
Mdm2 targets E7 for proteasome-mediated degradation. These results were 
further verified using immunofluorescence staining, and it can be seen that the 
nuclear staining of E7 was abolished in the presence of Mdm2 (Figure 24b, left 
panel). Interestingly, treating cells with proteasome inhibitors not only resulted in 
higher levels of E7 in the presence of Mdm2, but also led to the appearance of
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F igu re  23. M dmS binds to  E2 and E7 in  vitro.
In vitro translated and radiolabelled Mdm2 was incubated with bacterially 
purified G ST-tagged E 2 or E7 proteins. GST-alone and GST-p53 were 
included as negative and positive controls, respectively. The binding reaction 
was incubated on ice for lhr, and G ST proteins were washed extensively using 
a detergent containing buffer. Bound proteins were analysed using SDS-PAGE 
and autoradiography. Coomassie stain of the G ST inputs is also included in the 
upper panel. (*) indicates the full-length GST-fusion proteins.
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F igure 24. M dm 2 enhances th e  p ro teasom e m ed ia ted  d eg rad a tio n  o f  E7.
a) U 2 OS cells were transfected with a combination of pcDNA. 16E7, Mdm2, CDK2 
ad 16E2 expression plasmids in the combination indicated. 24hrs after transfection, 
treatm ent with proteasome inhibitors CBZ and LLnL (CBZ/LLnL) was conducted 
for Shrs, and protein expressions were analysed by W estern blotting using 
antibodies against 16E7, 16E2, Mdm2 and (3-gal as a transfection control, b) U 2 OS 
cells were transfected with 16E7 alone or with an Mdm2 expression plasmid. In the 
case of proteasome inhibition, cells were treated with proteasom e inhibitors 
(CBZ/LLnL) for 3hrs prior to fixation. The expression of E7 was analysed by 
immunofluorescence using antibodies against 16E7.
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nuclear domains that are absent in cells that express E7 alone (Figure 24b, right 
panel). Having shown previously that both E2 and CDK2 can stabilise E7, we 
further sought to test whether the expression of each protein can compete with 
Mdm2 in controlling the expression levels of E7. Figure 24a shows that the 
increasing levels of either E2 or CDK2 did not prevent Mdm2-mediated 
degradation of E7, suggesting that degradation of E7 by Mdm2 is not affected by 
its re-localisation with chromatin-bound E2, nor by its increased phosphorylation 
by CDK2.
To further confirm the Mdm2-mediated degradation of E7, we expressed E7 in 
U 2OS cells with siRNA that specifically targets Mdm2 transcripts (siMdm2). 48 
hrs after transfection, the cells were harvested and protein levels were detected by 
W estern blot. To confirm that endogenous Mdm2 protein levels were reduced in 
the presence of siMdm2, we compared the levels of p53, a well-known target of 
Mdm2, in cells transfected with siRNA against Luciferase (siLuc) with those 
transfected with siMdm2. As expected, siMdm2 increased the protein levels of p53 
when compared with the control transfection with siLuc (Figure 25a). 
Interestingly, the level of transfected E7 was also increased upon the knockdown of 
Mdm2 by siMdm2, suggesting that E7 levels can be controlled by endogenous 
Mdm2. In addition, we tested the half-life of E7 in mouse embryo fibroblast (MEF) 
cells that are both Mdm2 and p53 knockout (M dm2-/- p53-/-) and compared it 
with the half-life of E7 co-expressed with Mdm2 in the same cells. Figure 25b, left 
panel, shows that E7 has a prolonged half-life in M dm 2-/- p53-/- cells of up to 2 
hrs, which far exceeds the already established half-life of E7 in wild-type M EF cells 
of about 30 minutes (Oh et al, 2004a). Interestingly, the half-life of E7 is markedly 
reduced to about 15 minutes in the presence of Mdm2 (Figure 25b, right panel),
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resembling that of E7 expressed in U 20S (Figure lOe). Overall, these results 
provide evidence that Mdm2 can radically decrease the stability of E7.
E7 is targeted for degradation by Mdm2 at the sites of nuclear domains
W e were further interested in characterising the nuclear domains that appear as a 
result of co-expressing Mdm2 and E7 in the presence of proteasome inhibitors. 
Using immunofluorescence staining we can confirm that, in the presence of 
proteasome inhibitors, Mdm2-mediated degradation of E7 is inhibited, and that 
both proteins co-localise in nuclear domains (Figure 26a). Since it has been shown 
previously that PML bodies can act as sites of nuclear protein sequestration, we 
used polyclonal antibodies against endogenous PML proteins to show that these 
nuclear domains are also sites of PML protein localisation (Figure 26b). In 
addition, by staining cells with FK2 antibodies, which specifically recognise 
protein-bound but not free ubiquitin, these nuclear domains were found to be 
highly enriched in ubiquitinated proteins (Figure 26c). This demonstrates that 
inhibiting Mdm2-mediated degradation of E7 results in formation of nuclear 
domains that are rich in ubiquitinated proteins and where Mdm2, E7 and PML 
bodies co-localise, suggesting that Mdm2 mediates the degradation of E7 at 
specific sites in the nucleus.
The interaction between Mdm2 and E2 results in the increased 
transcriptional activity of E2
Since we observed no change in E2 levels in the presence of Mdm2 (Figure 27a), 
we sought to examine whether there are any potential effects upon each others
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Figure  25. T h e  knockdow n o f M dm 2 expression  increases th e  s tab ility  o f  E7.
a) siRNA knockdown of endogenous Mdm2 expression results in increased levels of 
E7. U 2 OS cells were transfected using Lipofectamine2000 with pcDNA. 16E7 and 
P-gal along with control siRNA or siRNA against Mdm2 (siMdm2). 48 hrs after 
transfection, protein levels were detected by W estern blot using an antibody 
against E7 or P~gal as a transfection control, b) The half life of E7 is prolonged in 
M dm 2-/- p53-/- M EF cell line. Cells were grown in 6-well plates, and transfected 
using Lipofectamine2()00 with pcDNA. 16E7 alone or with M dm2 expression 
plasmid. 24 hrs after transfection, cells were treated for different times (0, 15, 30, 60, 
90 and 150 minutes) with cycloheximide in DMSO or with DMSO alone for 150 
minutes. Cells were then harvested and the protein levels of E7 were analysed by 
W estern blot using monoclonal antibodies against 16E7 or P-gal as a m arker for 
transfection efficiency.
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F igure  26. M dm 2 m ed iates th e  re lo ca lisa tio n  o f  E7 in to  u b iq u itin  rich  nuclear 
dom ains.
U 2 OS cells expressing HA-E7 alone, or HA-E7 with M dm2 were left untreated or 
treated with proteasome inhibitors (CBZ) for Shrs prior to fixation. Cells were then 
stained using the following combinations of antibodies; rabbit anti-HA and mouse 
anti-M dm2 (a); mouse anti-HA and rabbit anti-PM L (b); rabbit anti-HA  and mouse 
anti-FK2 (c). The results obtained are representative of at least 3 independent 
experiments.
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activities. In order to verify that E2 and Mdm2 can form a complex in vivo, we 
performed a co-immunoprecipitation assay from 293 cells that are transfected with 
either Mdm2 alone or Mdm2 with GFP-tagged E2. Immunoprecipitation was 
conducted using antibodies against GFP to pull down E2 followed by W estern blot 
analysis using an anti-Mdm2 monoclonal antibody to detect immunoprecipitated 
proteins. Figure 27b shows that a complex between Mdm2 and E2 can be detected 
in cells expressing Mdm2 and E2, but not in cells expressing Mdm2 alone. 
Furthermore, to identify the region of E2 that mediates its interaction with Mdm2, 
we used a number of GST-tagged E2 fragments, including the N- and C-terminal 
domains and truncation fragments of the C-terminal domain (see Figure 7a). 
Figure 27c shows the results of an in vitro binding assay between the GST-tagged 
E2 fragments and in vitro translated Mdm2. It can be seen that E2 binds to Mdm2 
mainly through its C-terminal half and, more specifically, through a region 
spanning residues numbers 322-335. Since the C-terminal domain of E2 mediates 
its DNA binding, we sought to test whether Mdm2 can affect the transcriptional 
activity of E2. To do this, we performed a luciferase reporter assay using a 
construct that contains 6 synthetic tandem repeats of the E2 DNA-binding site 
upstream of the luciferase gene (see Figure 15a). This assay was performed in both 
U 20S and SAOS-2 cells to rule out the effects of p53 and pRB inactivation induced 
by Mdm2. The cells were transfected with the reporter plasmid together with 
GFP-tagged E2 and Mdm2 expression plasmids and luciferase activity was assayed 
24 hrs after transfection. As can be seen in Figure 27d, the expression of Mdm2 
strongly enhances the transcriptional activity of E2 in both cell lines, showing that 
Mdm2 enhances E2’s transcriptional activity in a manner independent of p53 and 
pRB inactivation by Mdm2.
61
Results
The expression o f E2 inhibits Mdm2-mediated degradation o f p53 and pRB
To test the effects of E2 on the activities of Mdm2, we then examined the ability of 
Mdm2 to degrade p53 and pRB in the presence of E2. This was done by transiently 
expressing FLAG-tagged p53 in U 20S cells and pRB in SAOS-2 cells, together 
with Mdm2 and E2 as indicated. Figures 28a&b show that E2 can strongly inhibit 
Mdm2-mediated degradation of both pRB and p53. In the absence of Mdm2, E2 
expression has no effect on pRB levels, but results in an increase of p53 levels in 
both soluble and insoluble fractions of the cell extract (Figure 28b). This could be 
the result of the previously described interaction between p53 and E2 (Massimi et 
al, 1999). These results suggest that E2 can inhibit Mdm2 mediated degradation of 
both pRB and p53.
The activity of E2 in opposing Mdm2-mediated degradation of its substrates was 
further confirmed using immunofluorescence. Both p53 and E2 are diffused in the 
nucleus when co-expressed in untreated U 2OS cells or in cells treated with 
proteasome inhibitors (Figure 29a). Upon the addition of Mdm2 expression 
plasmid, the expression of p53 is still detected, thereby confirming the W estern 
blot analysis in Figure 28b. In these cells however, both p53 and E2 become less 
diffused in the nucleus even in the absence of proteasome inhibitors (Figure 29b, 
upper panel). Treating these cells with proteasome inhibitors, E2 and Mdm2 form 
more discrete nuclear domains (Figure 29b, lower panel).
We were then interested in characterising the nuclear structures that form in cells 
treated with proteasome inhibitors and express Mdm2. First, we show that in the 
absence of Mdm2, E2 has a diffused nuclear staining that remains unchanged in the 
presence of proteasome inhibitors (Figure 30a). The additional expression of 
Mdm2 does not greatly affect the localisation of E2 (Figure 30b, upper panel),
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Figure 27. Mdm2 interacts with 16E2 both in vitro and in vivo.
a) The effect of Mdm2 expression on E2 levels was tested by expressing both 
proteins in U 20S  cells. 24hrs after transfection, protein levels were analysed, in 
both the soluble and insoluble fraction of the cell, by W estern  blot using antibodies 
against 16E2 or f3-gal as a transfection control, b) E2 and Mdm2 bind in vivo. 293 
cells were transfected using either Mdin2 alone or Mdm2 with G FP-tagged E2. 
Cell extracts were immunoprecipitated using anti-G FP antibodies followed by 
W estern blot analysis using antibodies against Mdm2 or G FP. (*) indicate non­
specific bands.
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Figure 27. Mdm2 interacts with 16E2 both in vitro and in vivo. (cont.) 
c) Mdm2 binds to the C-term inal of E 2. GST-16E2 and a number of G ST -tagged 
fragments of E2 (figure 7a) were incubated with in vitro translated and 
radiolabelled Mdm2. Binding reactions were incubated for 1 hr on ice, and bound 
proteins were analysed using SDS PAGE and autoradiography. 50% of the input is 
included and the G ST inputs are shown below stained with coomassie where (*) 
indicate the full-length GSTs. d) Mdm2 enhances E2-mediated transcriptional 
activity. U 2 OS and SAOS-2 cells were transfected with reporter construct 
containing 6X E2 binding sites upstream the luciferase gene, plus the Remlla 
luciferase gene as a transfection control and a G FP-E2 expression vector with or 
without the expression of Mdm2. Representative results of three experim ents are 
shown together with standard deviation.
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F igure  28. E2 inh ib its  M dm 2 m ed ia ted  d eg rad a tio n  o f  pRB and p53.
a) SAOS-2 cells were transfected with a pRB expression plasmid, along with a 
combination of 16E2 and Mdm2 expression plasmids as indicated. Proteins levels 
were assessed by W estern blot 24hrs post transfection using antibodies against 
pRB or G FP as a transfection control, b) p53 degradation by Mdm2 was assessed 
in U 2 OS cells by the expression of FLAG-tagged p53 construct along with a 
combination of E2 and Mdm2 expression plasmids as indicated. T he levels of p53 
were assessed by W estern blot using anti-FLAG antibodies.
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F igure  29. E2 is localised  w ith  p 53 in  specific nuclear s tru c tu re s  in  th e  
p resence o f  M dm 2.
U 2 OS cells were transfected with FLAG-tagged p53 and E2 expression plasmids in 
the absence (a) or the presence (b) of an Mdm2 expression plasmid. Cells were 
transfected in duplicates and one set was treated with proteasom e inhibitors (a&b 
lower panels). The expression of p53 and E2 was visualised using monoclonal anti- 
FLAG and polyclonal anti-E2 antibodies. Images were scanned using confocal 
microscopy. The results obtained are representative of at least 3 independent 
experiments.
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F igu re  30. E2 is localised  to  nuclear s tru c tu re s  in th e  p resence  o f  M dm 2
a) The expression of E 2 is unchanged in the absence of M dm2 expression in cells 
that are treated with proteasome inhibitors. U 20S  expressing E2 were stained using 
monoclonal anti-E2 and polyclonal anti-PM L antibodies, b) E 2 and Mdm2 co- 
localise. U 2 OS cells were transfected with E 2 and Mdm2 expression plasmids in 
duplicates, and one set of transfections was treated with proteasom e inhibitors for 
3hrs prior to fixation (lower panel). Cells were stained with polyclonal anti-E2 and 
monoclonal anti-M dm2 antibodies, c) The relocalisation of E 2 with Mdm2 is 
independent on its interaction with p53. SAOS-2 and M dm 2-/- p 5 3 -/-  M E F cells 
were transfected with E2 and Mdm2 expression plasmids. 24 hrs after transfection 
cells were treated with proteasome inhibitors and stained as in (b). The results 
obtained are representative of at least 3 independent experiments.
Figure 30 (cont.)
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Results
however, upon treatment with proteasome inhibitors, cells that express both 
Mdm2 and E2 form nuclear domains in which both proteins co-localise (Figure 
30b, lower panel). Furthermore, to show that the re-localisation of E2 by Mdm2 to 
these nuclear domains is independent on its binding to p53, we repeated the same 
experiment and expressed E2 with Mdm2 in p53 negative cells including SAOS-2 
and M dm 2-/- p53-/- M EF cells. Figure 30c shows that the relocalisation of E2 by 
Mdm2 in the presence of proteasome inhibitors is independent on the binding of 
E2 to p53. Overall, these results show that the expression of Mdm2 is essential for 
the relocalisation of E2 to specific structures within the nucleus.
The nuclear domains we observe resemble nuclear bodies that assemble as a result 
of cellular stress induced by the inhibition of the proteasome, and have been 
previously shown to be sites where PML domains, Mdm2 and nucleoli co-localise 
(Bernardi et al, 2004; Kurki et al, 2003). They are also sites where the activities of 
pro-apoptotic proteins such as p53 and Daxx are controlled. To characterise 
whether the nuclear domains observed in our assays correspond to nuclear stress 
bodies, cells expressing Mdm2 and E2 were treated with proteasome inhibitors and 
stained using antibodies against endogenous p53, Daxx, PML, nucleoli (C23 
antibody) and ubiquitinated proteins (FK2 antibody). Indeed, Figure 31 shows that 
upon the expression of Mdm2, E2 co-localises with components of nuclear stress 
bodies indicating that E2 can regulate Mdm2-mediated degradation of p53 and is 
localised by Mdm2 to nuclear stress bodies, which contain components of PM L 
bodies (in the case of p53, PML and Daxx) as well as nucleolar structures and are 
enriched in polyubiquitinated proteins. This confirms that these structures are 
stress-induced nuclear bodies (Bernardi et al, 2004; Kurki et al, 2003).
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Finally, having shown that E2 inhibits Mdm2-mediated degradation of p53 and can 
co-localise with p53 at ubiquitin-rich nuclear domains, we were interested to 
investigate whether pRB, is also re-localised to these nuclear domains. In order to 
investigate this, U 2OS cells were transfected with E2, Mdm2 and pRB expression 
plasmids. The results in Figure 32a show that both pRB and E2 are diffused in the 
nucleus in untreated cells (upper panel), however in cells that are treated with 
proteasome inhibitors pRB does not localise with E2 (lower panel) or with Mdm2 
(Figure 32b) at nuclear domains. These results indicate that E2 rescues Mdm2- 
mediated degradation of pRB but does not co-localise with pRB at nuclear domains.
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F igure 31. E2  and M dm 2 co-localise in  nuclear s tre ss  bodies in cells tre a te d  
w ith  p ro teaso m e inh ib ito rs .
U 20S  cells were transfected with E 2 and Mdm2. 24hrs after transfection, cells 
were treated with proteasome inhibitors for 3hrs prior to fixation. Anti-E2 
antibodies were used to stain cells along with antibodies against endogenous 
proteins including, Daxx, p53, FK2, C23 and p53. The cross-talk between the 
green and red channels was avoided by the use of two separate excitation 
wavelengths as indicated in M aterials and Methods. Relevant subcellular 
structures are labelled with white boxes and enlarged on the lower left side of the 
merged image. The results obtained are representative of at least 3 independent 
experiments.
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F igure  32. pRB does n o t localise w ith  E2 and M dm 2 in  U 2 OS cells.
U 2 OS cells were transfected with E2, Mdm2 and either pRb or H A-tagged pRB 
expression plasmids. 24hrs, cells were left untreated or treated with proteasom e 
inhibitors as indicated. Cells were then fixed and stained with polyclonal anti-E2 
and monoclonal anti-pRB (a) or monoclonal anti-M dm2 and polyclonal anti-HA 
(b). Relevant subcellular structures are labelled with white boxes and enlarged on 
the lower left side of the merged image. The results obtained are representative of 
at least 3 independent experiments.
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D iscussion
Unlike lytic viruses, HP Vs can replicate their DNA and release infectious virions 
without causing the death or transformation of their host cells. The virus initially 
infects the basal layer of the epithelium and the production of mature virions is 
only observed in the upper granular layer (Howley & Lowy, 2001). W ith respect to 
the papillomavirus life cycle, viral genome integration and cellular immortalisation 
are both disadvantageous for the virus; the replicative capacity of the virus is lost 
with the loss of the E2 protein and immortalised cells are unable to differentiate 
into the stratum corneum where mature virions are formed and shed (Figure 3). 
Therefore, to ensure an efficient and productive life cycle, HPVs finely modulate 
the activities of cellular proteins and their own viral gene products by means of 
various interactions. In this study, we have identified several mechanisms involving 
both viral and cellular gene products that modulate the activities of HPV-16 E7, 
whose expression is upregulated in cervical cancer (figure 33a). These include 
direct binding between E7 and the viral transcriptional activator E2, 
phosphorylation of E7 by CDK2 and CKII, plus interaction of E7 with Mdm2.
Interplay between HPV-16 E2 and E7
Several studies have shown transcriptional regulation of the viral oncoproteins, E6 
and E7, by E2 (Cripe et al, 1987; Dowhanick et al, 1995; Goodwin & DiMaio, 
2000). Other studies show that E2 can, additionally, control the oncogenicity of E6 
and E7 in a transcriptionally-independent manner. Both HPV-16 and -18 E2 
proteins can induce apoptosis in HPV-positive cell lines in the absence of their
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DNA-binding domains (Blachon & Demeret, 2003; Demeret et al, 2003; W ebster et 
al, 2000). In addition, it has been previously shown that mutations in the E2 
binding sites proximal to the p97 promoter do not fully alleviate E2-mediated 
repression of HPV-16-induced immortalisation of primary human keratinocytes 
(Romanczuk & Howley, 1992). Overall, these studies provide evidence of a 
transcriptionally-independent capability of E2 to counteract the activity of the viral 
oncoproteins. In this study we propose a novel post-transcriptional mechanism by 
which E2 interferes with the oncogenicity of E7 through direct interaction between 
the two proteins. This interaction seems to be specific to high-risk and not low-risk 
HPV types (Figure 6d), thus suggesting its relevance to the life cycle of high-risk 
HPV types, although we cannot exclude that the interaction between low-risk E2 
and E7 may occur at a lower affinity or under certain conditions. The interaction 
between HPV-16 E2 and E7 is demonstrated using both in vitro and in vivo binding 
assays and is supported by a series of functional assays.
Mapping site o f interaction between E2 and E7
The site of interaction between the E2 and E7 maps to the middle hinge region of 
E2 which is highly unconserved between E2 proteins from different HPV types. 
Only a small number of proteins was shown to bind to this region of E2 from 
various papillomavirus types, including the binding of HPV-8 E2 to sp 1 (Steger et 
al, 2002) and HPV-5 E2 to SR proteins (Lai et al, 1999). In addition, NLS and CKII 
phosphorylation sites that affect the localisation of HPV-11 E2 and the stability of 
BPV-1 E2, respectively, are both located at the hinge region (Penrose et al, 2004; 
Zou et al, 2000). Interestingly, unlike the DNA binding and dimerisation domains 
of E2 that are conserved in E2 proteins from various HPV types, protein
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interactions and modifications of the hinge region are poorly conserved between 
different E2. This suggests one mechanism by which the binding of E7 to E2, 
mediated by the hinge region, may be specific to only certain HPV types. On the 
E7 protein, the CR3 domain mediates its interaction with E2 through a region 
spanning residues number 79 to 83. This region of E7 has been shown consist 
largely of hydrophobic residues which are important for the structural integrity of 
the E7 protein (Ohlenschlager et al, 2006). However, the use of the 79-83 mutant 
of E7 did not abolish its binding to a number of other cellular targets (Baldwin et 
al, 2006; Bernat et al, 2003; Huh et al, 2005) suggesting that this mutant still 
retains some structural integrity and activities of the wild-type E7 protein. 
Hydrophobic residues were also shown to mediate protein-protein interactions 
(Jones & Thornton, 1996). Indeed, the CR.3 domain of E7 binds to several cellular 
targets (see below). The binding of E2 to this region of E7 may therefore be 
important in regulating the interaction of E7 with several of its cellular targets.
E2 increases the stability o fE 7
E2 and E7 can modulate each other’s activities in vivo. The expression of E2 
markedly increased the levels of both endogenous and transiently over-expressed 
E7. Although E2 can act as both transcriptional activator and repressor in a 
concentration-dependent manner (Steger & Corbach, 1997), we excluded the role of 
E2’s transcriptional activity in increasing the levels of E7 for the following reasons. 
First, E7’s levels were stabilised by E2 even in the absence of an E2 binding site on 
the E7 promoter as both proteins were over-expressed in U 20S cells from pcDNA 
expression plasmids. Second, in U 20S cells, as well as in CaSKi cells which contain 
the viral LCR, the half-life of E7 was increased in the presence of exogenous E2. In
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CaSKi cells, this effect was also independent of the HPV mRNA levels, since at the 
specific concentrations of E2 and incubation time used in this study we observed no 
major alterations in E6/E7 mRNA levels as determined by RT-PCR. Finally, the 
levels of the A4 mutant of E7, which is defective in binding E2, were not changed 
upon the introduction of E2, thus providing further evidence that the stability of 
E7 is increased due to direct protein—protein interaction between the two proteins. 
E2 may alternatively stabilise E7 by recruiting it to the insoluble fraction of the 
cell (Figure 11), inhibiting its interaction with the proteasome (Berezutskaya & 
Bagchi, 1997; Oh et al, 2004a) or by enhancing the phosphorylation of E7 which is 
an important regulator of its stability (see below).
Inhibition ofE 7 co-transforming activity in the presence ofE2
W e also observed an effect of E2 on inhibiting E7’s growth-promoting function in 
primary rodent cells in the absence of any E2-mediated transcriptional modulation. 
The ability of E7 to cooperate with an activated EJ-itas oncoprotein in the 
transformation of primary rodent cells depends on its capacity to interfere with the 
activity of various cell cycle regulatory proteins (Davies et al, 1993; Zerfass et al,
1995). Although binding to and disrupting the function of pRB is considered to be 
a major oncogenic activity of E7, many studies have shown that this binding is 
dispensable in some E7-induced phenotypes and is insufficient for E7-induced 
transformation (Balsitis et al, 2003; Banks et al, 1990; Brokaw et al, 1994; Jewers et 
al, 1992; Oh et al, 2004b). Here we show that E2 can interfere with both E7- 
mediated degradation of pRB (Figure 14) and pRB-independent activities of E7, 
such as inducing centrosome over-duplication (Figure 13) (Duensing & Munger,
2003). Our assays indicate that E2 can regulate E7’s functions through two
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possible pathways. First, the in vitro binding assays showed that E2 binds directly 
to the C-terminal half of E7 (Figure 7) at a region where several cellular targets of 
E7 also bind; such as TBP (Massimi et al, 1997), Mi2|3-NURD histone deacetylase 
complex (Brehm et al, 1999) and the API transcription factor (Antinore et al, 
1996). Therefore, the binding of E2 to E7 might compete with the binding of E7 to 
some of its cellular targets and thus inhibit its activities. Secondly, E2 may repress 
the activity of E7 by changing the localisation of E7 to insoluble compartments 
within the cell (Figure ll) . By doing so, E2 can inhibit the interaction of E7 with 
several of its cellular partners and possibly redirects E7’s activities to other, as yet 
unidentified, cellular targets. In a normal viral life cycle, the ability of E7 to form a 
complex with E2 might widen the repertoire of its cellular targets which may be 
important for a productive viral life cycle. These additional activities of E7 would 
therefore cease when the expression of E2 is lost as a consequence of viral genome 
integration.
Reversion o f E7-induced centrosome over-duplication by E2
The exact mechanism by which HPV infections induce centrosomal abnormalities 
is still unknown. The incidence of cells harbouring abnormal centrosome numbers 
increases with the progression of HPV-induced carcinogenesis (Skyldberg et al,
2001) suggesting that the upregulation of E6 and E7 expression is linked to the 
severity of centrosome abnormality. Both E6 and E7 were shown to be capable of 
increasing centrosome numbers in cells (Duensing & Munger, 2002a) where the 
activities of E7 seems to directly induce centrosome over-duplication (see below). 
Numeric centrosome abnormalities, however, are also seen in raft cultures 
harbouring both wild-type HPV-16 genomes as well as genomes mutated in E7
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expression (Duensing et al, 2001b) indicating that centrosome over-duplication can 
occur in early stages of HPV-associated carcinogenesis and possibly as a result of 
E6 expression alone. Our results are consistent with this observation for the 
following reasons. W e observe that the expression of E2 can inhibit centrosome 
abnormalities induced by E7, therefore in raft cultures harbouring wild-type HPV 
genomes, the expression of E2 leads to a phenotype of centrosome numbers that is 
comparable to raft cultures harbouring mutated HPV genomes with disrupted E7 
expression. In addition, the ability of E6 to induce centrosome abnormalities is 
thought to be an indirect result of its activities, such as degrading p53 (see below), 
which is not inhibited in the presence of E2 (Grm et al, 2005).
There are various mechanisms by which the expression of E7 can lead to 
centrosome abnormalities. The activation of cyclins A and E by E7, which are 
involved in centrosome duplication (Matsumoto et al, 2006; Meraldi et al, 1999), 
may be one such possibility. It will therefore be interesting to investigate the 
effects of E2 on this activity of E7, in order to determine which might contribute to 
its inhibition of E7-induced centrosomal abnormalities. Furthermore, it would be 
also interesting to investigate the activity of the SCF-ubiquitin ligase complex in 
the presence of E2; the SCF complex not only binds and regulates the stability of 
E7 (Oh et al, 2004a), but is also shown to localise to the centrosome (Freed et al, 
1999) and its loss of expression results in genomic instability and centrosome over­
duplication (Nakayama et al, 2000). E7 may mediate some of its centrosome 
amplification activities through binding to components of the SCF complex and its 
eventual destabilisation by the complex may be only an indirect consequence of this 
interaction. The expression of E2 may not only inhibit SCF-mediated degradation 
of E7, resulting in its increased stability, but may also inhibit SCF-dependent
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centrosome over-duplication mediated by E7. Other unknown cellular targets 
regulated by E7, which may contribute to E7-induced centrosome abnormalities, 
may also be targeted by E2. Our results however cannot rule out the possibility 
that E2 can inhibit E7’s activities, in both centrosomal abnormalities and primary 
cell transformation assays, via additional mechanisms that are independent of its 
interaction with E7. Indeed, we have also observed that E2 can interfere with some 
activities of cellular oncoproteins, such as Mdm2, which leads to the rescue of 
proteasome-mediated degradation of both p53 and pRB (discussed below). W e 
speculate that this activity of E2 does not correlate with its inhibition of E7- 
mediated centrosome abnormalities since pRB degradation by E7 has been shown 
to be dispensable for this activity of E7 (Duensing & Munger, 2003) and p53 
degradation induced by E6 does not induce centrosome abnormalities in transient 
transfection assays (discussed further below) (Duensing et al, 2000).
E7 enhances E 2 ’s transcriptional activity
E2-induced re-localisation of E7 to the more insoluble fraction of the cell suggests 
that E2 may recruit E7 onto the chromatin; E2’s previously reported localisation 
(Donaldson et al, 2007; Kurg et al, 2005). W e considered that this re-localisation of 
E7 may be relevant for some of E2’s activities and so investigated the effects of E7 
on two functions of E2 including transcriptional activation and binding to mitotic 
chromosomes. The expression of E7 along with E2 in a transient transcriptional 
activation assay enhances E2’s transcriptional activity. W e show that the levels of 
E2 are unchanged in the presence of E7 in this assay, therefore alternative 
mechanisms by which E7 can enhance this activity of E2 have to be considered. 
These may include modulating E2 DNA binding affinity or the recruitment of
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factors required for optimal E2 transcriptional activity by E7. In the latter case, E7 
has been shown to bind to several transcriptional factors including TBP (Massimi 
et al, 1997) which is also involved in E2-mediated transcriptional activation. Both 
E2 and TBP bind to the same region on E7. The ability of E7 to dimerise 
(Zwerschke et al, 1996) may bring both proteins into close proximity by allowing 
each protein to bind to each of E7 molecule within a dimer. In addition, the binding 
of E7 to other transcriptional factors, such as API (Antinore et al, 1996), MPP2 
(Luscher-Firzlaff et al, 1999), c-myc (Wang et al, 2007) and E2Fl (Hwang et al,
2002), and transcriptional modulators, such as pCAF (Avvakumov et al, 2003) and 
histone deacetylase (Brehm et al, 1999), may also play a role in mediating E7’s 
enhancement of E2’s transcriptional activity. Obviously, these hypotheses need to 
be further confirmed by, for an example, chromatin-immunoprecipitation to detect 
E7-mediated changes in the constitution of protein complexes that bind along with 
E2 on the DNA, as well as to confirm that E7 is actually present at the HPV 
promoter in the presence of E2.
Localisation ofE 7 with E2 on mitotic chromosomes
W e also found an intriguing co-localisation of E7 with E2 on mitotic 
chromosomes. The first suggestion that a papillomavirus-encoded protein can 
associate with mitotic chromosomes came from a study of BPV E2 (Skiadopoulos & 
McBride, 1998). BPV E2 was shown to bind to the bromodomain-containing 
protein, Brd4 (You et al, 2004), which attaches to acetylated chromatin during 
interphase and mitosis (Dey et al, 2003). Although BPV and HPV E2 proteins 
display identical DNA-sequence specificity and similar functions, they vary in some 
of their characteristics (Bouvard et al, 1994a; Hines et al, 1998). Here, we have
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observed that HPV-16 E2 also possesses a chromosome-association phenotype but, 
unlike BPV-1 E2, it localises to chromosomes only at late stages of mitosis. This is 
in agreement with previous studies showing that HPV-16 E2, as well as other 
alpha papillomaviruses E2 proteins, closely associate with mitotic chromosomes at 
telophase but not at anaphase or metaphase (McPhillips et al, 2006). However, 
unlike that study, we did not oberve the chromosomal localisation of HPV-16 E2 at 
prophase. In addition, the exclusion of HPV-16 E2 from metaphase chromosomes 
was shown in another study (Van Tine et al, 2004). In contrast to that study, we 
did not observe a pattern of HPV-16 E2 expression that indicates its localisation to 
mitotic spindles or centrosomes. These differences might be due to variations in 
cell lines, expression levels of E2, as well as detection and fixation procedures used. 
Further studies are required to clarify these issues.
Most interestingly, we observed that 16E2 re-localises E7, but not E6, to mitotic 
chromosomes at telophase. This suggests that the re-localisation of E7 by E2 is a 
highly specific event. This was further borne out by the use of an E7 mutation that 
prevents its binding to E2, which likewise also failed to co-localise with E2 on 
mitotic chromosomes. At this stage we cannot exclude the possibility that this E7 
mutation may have other properties which preclude E2 stabilisation and 
recruitment to chromosomes, and future studies will aim to clarify this by using E2 
mutations that are defective for binding to E7. The biological consequence of this 
specific localisation is also still unidentified and it remains to be determined 
whether E2 alters E7 patterns of expression in the context of a normal viral life 
cycle. This could be investigated using raft culture models of HPV infection. 
However, these studies are particularly intriguing when one considers the effects of 
E6 and E7 upon mitosis, where both have been shown to separately induce mitotic
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abnormalities when stably expressed in cultured cell-lines or cells derived from 
transgenic mice (Duensing & Munger, 2002; Patel et al, 2004; Schaeffer et al,
2004). Further dissection of the role of each protein showed that, when each 
protein is transiently expressed, only E7 results in immediate chromosomal 
abnormalities (Duensing et al, 2001a; Duensing et al, 2000). This suggests that E7 
has a direct effect in inducing centrosomal abnormalities, while the effects induced 
by E6 might be an indirect consequence of the abrogation of p53 function. 
Together with the direct role of E7 in interfering with the mitotic machinery, the 
tethering of E7 to mitotic chromosomes may be required to directly inhibit the 
cellular checkpoint proteins that might be activated in response to the detection of 
E2 on mitotic chromosomes, thus avoiding cell cycle arrest in mitosis. Another 
possible function would be to segregate E7 itself and thus ensure that appropriate 
amounts of the protein will be present in newly divided daughter cells. E7 might 
also be required to stabilise the binding of E2 to the viral episomes or mitotic DNA 
during cell division and current studies are aimed towards assessing the effects of 
E7 upon E2 during exit from mitosis.
Conclusions: E2-E7 interaction
Overall, these results provide evidence of a novel interplay between the HPV-16 
E2 and E7 proteins that may be of relevance during the viral life cycle. In lower 
basal layers of the epithelium, the localisation of E7 with E2 on mitotic 
chromosomes may play a role in viral genome segregation which acts to insure the 
maintenance of viral infection and the progression of viral genomes to upper 
epithelial layers where the virus completes its life cycle. In this layer, both E2 and 
E7 are thought to be expressed at low levels, reviewed by (Doorbar, 2005). Further
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evidence that both proteins are expressed in this layer, as well as the upper 
epithelial layers, comes from the analysis of viral transcripts in transgenic mice 
(Sethi & Palefsky, 2004). The expression of E7 was also shown to overlap with E4 
in upper epithelial layers where viral genome amplification and high expression of 
E2 are expected to take place (Middleton et al, 2003). Overall, these studies 
suggest that both E2 and E7 can be expressed simultaneously from early to late 
stages of the viral life cycle and therefore may modulate each other’s activities.
E7, as well as E6 (Grm et al, 2005), can enhance E2 transcriptional activity. This 
enhancement could occur in the lower epithelial layers where the expression of E7 
is important for S-phase re-entry of these cells, or in the middle epithelial layer 
where viral genome amplification takes place. In the latter layer, the expression of 
E7, and E6, can delay repression of their own transcripts induced by high levels of 
E2 and therefore prolong viral genome amplification. But whether E7 acts by 
enhancing E2’s transcriptional activation or by delaying transcriptional inhibition 
remains to be investigated. This enhancement of E2’s transcriptional activity by 
the viral oncoproteins is particularly relevant for the high-risk HPV types which 
replicate their genomes in upper epithelial layers, in contrast to low-risk HPV 
types which replicate their genomes in lower epithelial layers where the cellular 
DNA replication machinery is normally still present (Doorbar, 2005). Our results 
indicate that E2 and E7 from high-risk HPV types interact at a higher affinity 
compared to the equivalent proteins derived from low-risk HPV types (Figure 6d), 
therefore the stimulation of E2 transcriptional activity by E7, as well as E6, may 
relate to the epithelial layer where viral genome amplification takes place.
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In addition, our results show that E2 can inhibit certain activities of E7 which are 
relevant for cellular transformation and genomic instability. The avoidance of cell 
transformation in the lower epithelial layer is important to ensure that cellular 
differentiation is not completely disrupted as a result of E7’s activities. By 
controlling the activities of E7 post-transcriptionally, E2 can maintain the levels of 
E7 and may act as an ON-and-OFF regulator permitting specific activities of E7 
only under certain conditions. The presence of external stimuli (Bosch et al, 2002) 
may disrupt the E2/E7 interaction stimulating the development of HPV-induced 
carcinogenesis.
W e also show that the expression of E2 inhibited E7-mediated degradation of pRB. 
In contrast, a previous study characterising the interaction between the E2 and E6 
proteins shows that the expression of E2 does not inhibit E6-mediated degradation 
of p53 (Grm et al, 2005). This indicates that while it is necessary for the virus to 
circumvent p53-mediated cellular apoptosis at early stages of the viral infection, 
the activity of pRB, which is also involved in cellular differentiation (Nguyen & 
McCance, 2005), is finely regulated by the viral proteins. The prevention of 
apoptosis, by E6, and the induction of cellular differentiation, possibly due to the 
activities of pRB, are important to ensure the production of mature viral particles 
prior to their release at upper epithelial layers.
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Regulation o f E7 by phosphorylation and the proteasome
Identification o f a potential P inl binding site on E7
Since it was shown that multiple mechanisms were responsible for regulating the 
function of E7 (Chien et al, 2000; Francis et al, 2000; Oh et al, 2004a), we were also 
interested in further exploring these aspects. Obviously, CKII phosphorylation has 
been shown to be critical in this, although it seems likely that there are still 
numerous gaps in our knowledge of how this is regulated. In this study we provide 
evidences of the existence of additional phosphorylation events on E7 that have not 
been described so far. These were initially based on the observation that inhibiting 
the dephosphorylation of E7 by the PP2A inhibitor, okadaic acid, results in the 
stabilisation of both wild-type E7 and a mutant of E7 that cannot be 
phosphorylated by CKII (Figure 19). We therefore analysed the HPV-16 E7 
sequence for the presence of consensus sites of other cellular kinases, in addition to 
CKII, and although there were several potential sites, none of them matched with a 
high score. We also checked for the consensus site for P inl, which is upregulated in 
a number of cancers and whose over-expression is associated with centrosomal 
abnormalities (Mantovani et al, 2004; Suizu et al, 2006). P inl as has also been 
shown to bind to HBV x-protein (HBx) and increase its stability as well as HBx- 
mediated transactivation (Pang et al, 2007). HPV-16 E7 contains one potential 
P inl binding site (TP) located at its extreme N-terminal domain (amino acids 5 
and 6). Since P inl requires the phosphorylation of the threonine or serine residue 
before binding (W ulf et al, 2005), amino acid number 5 of HPV-16 E7 is expected 
to be potentially phosphorylated. The binding of Pinl to E7 increases the level of
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E7 and may enhance its oncogenicity and mediate some of its centrosomal 
abrogation activities.
The activity o f CDKs is important fo r  the stability o fE 7
The Pin 1 binding site matches the minimum consensus of a CDK phosphorylation 
site so we hypothesised that threonine 5 of HPV-16 E7 may be recognised by 
CDKs for phosphorylation. Here we show that E7 can be phosphorylated in vitro 
by CDK2 and that the activity of CDK2 is important in controlling the stability of 
E7 in vivo. Since E7 has been shown to increase the activity of CDK2 (He et al, 
2003) and the expression of cyclin E and cyclin A (Zerfass et al, 1995), it is possible 
that by doing so, E7 can act positively on increasing its own protein stability. Both 
HPV-16 and HPV-18 E7 were shown previously to bind to CDK2-containing 
complexes (He et al, 2003; McIntyre et al, 1996). In the case of HPV-18 E7, its 
binding to the CDK2/cyclin E complex was shown to be indirect, but mediated by 
pl07 (McIntyre et al, 1996). When we scanned the HPV-18 E7 sequence we found 
that it contained neither a potential CDK phosphorylation site nor a cyclin binding 
motif (RXL), therefore indicating that HPV-18 E7 cannot directly interact with 
cyclins and that this interaction is probably not conserved between E7 proteins 
from different HPV types. In contrast, HPV-16 E7 contains one potential cyclin 
binding site which spans amino acids 77-79 as well as a potential CDK2 
phosphorylation site at its N-terminal half. The exact residues that are 
phosphorylated on E7 by CDK2 are still to be determined. M utants of E7 in both 
the 5th and 7th threonines are still phosphorylated in vitro by CDK2 and are 
stabilised upon the expression of CDK2 in vivo, therefore indicating the possibility 
of additional CDK phosphorylation sites on E7. This is also supported by the result
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that these mutants of E7 still retain their ability to bind Pin 1 in vitro (data not 
shown). Furthermore, the binding of the CDK/cyclin complex to HPV-16 E7 by 
itself may result in its increased stability where the cyclins play an important role 
in mediating CDK recognition of their substrates. The A3 mutant of E7, which 
contains a disrupted RXL motif, and the N-terminal half fragment, however, are 
still phosphorylated in vitro. It is also possible that CDK2 stabilises E7 indirectly 
through a third, yet unidentified, proteins which can directly affect the stability of 
E7.
The precise CDK/cyclin complex that can most efficiently phosphorylate E7 in 
vivo is still to be determined. We observed an increase in the stability of E7 in 
G l/S-phase of the cell cycle indicating that the CDK2/cyclin E may mediate E7 
phosphorylation. However, we cannot exclude the role of other CDK complexes, 
such as CDK4/cyclin D which are also active at the G l/S-phase (Massague, 2004). 
At this stage of the cell cycle, the activity of E7 is important in inducing S-phase 
progression by mediating pRB degradation as well as interfering with initial stages 
of the centrosome duplication cycle; therefore increasing the stability of E7 
through the activity of CDKs may enhance some of E7’s activities.
The role of CDK/cyclin complexes in mediating the stability of E7 may be 
indirectly linked to previously published observations. First, the SCF complex 
containing the F box proteins, Skp2, which has also been shown to degrade cyclin 
E (Strohmaier et al, 2001) was shown to result in reduced stability of the E7 
protein (Oh et al, 2004a). Second, the use of CDK inhibitors abolished centrosome 
abnormalities induced by E7 (Duensing et al, 2004). In this case, the authors did 
not monitor the protein levels of E7 in the presence of the CDK inhibitors. Our
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results indicate that the activity of CDK2 is important for the stability of E7, 
therefore reducing the activity of CDK2, through the expression of the SCF 
complex or the use of CDK inhibitory molecules, may destabilise E7 and 
consequently reduce its activity.
CKIIphosphorylation o fE 7 regulates its stability
CKII phosphorylation of E7 was previously shown to enhance its ability to 
promote S-phase progression (Chien et al, 2000) and cellular transformation 
(Firzlaff et al, 1991). Here we show that the phosphorylation of E7 by CKII is also 
important for its stability (Figure 20) suggesting that mutants of E7 that cannot be 
phosphorylated by CKII may be reduced in their activities as a result of their 
decreased stability. Analysing the half-life of the CKII mutant of E7 in comparison 
to the wild-type protein would be a direct way to address this. The stability of E7 
appears to be dramatically decreased upon the individual inhibition of either CDK2 
or CKII (Figure 20) therefore indicating that the activities of both kinases are not 
redundant and that inhibiting the activity of one kinase is not compensated by the 
other. Phosphorylation of E7 by CKII was previously shown to affect its structural 
conformation (Kee et al, 1998) which may modulate its binding capacity to other 
proteins. Indeed, CKII phosphorylation was previously shown to enhance complex 
formation between E7 and TBP (Massimi et al, 1996). These results suggest that 
phosphorylation of E7, by either CKII or CDK2, may modulate its cellular 
localisation as well as its ubiquitination and interaction with the proteasome which 
may therefore affect its stability.
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The role o f Mdm2 in regulating E2 and E7
Mdm2 acceleratesproteasome-mediated degradation ofE 7
W e also propose a third novel mechanism by which the activities of HPV-16 E7 
can be controlled. This involves the interaction of E7 with Mdm2 and its 
consequent degradation by the proteasome. Evidence from a number of 
experiments support this hypothesis including transient expression assays, RNA- 
interference, half-life experiments and indirect immunofluorescence. First, 
inhibiting the expression of Mdm2 using siRNA against Mdm2 results in increased 
expression levels of E7 when expressed transiently in U 2 OS cells. Secondly, we 
observed a prolonged half-life of E7 in M dm 2-/- p53-/- M EF cells (up to 2 hrs) 
that greatly exceeds the half-life of E7 observed in U 2OS cells (between 15 and 30 
min) which do not express the Mdm2 inhibitor, pl4ARF. The ectopic expression of 
Mdm2 in M dm 2-/- p53-/- cells resulted in a reduced half-life of E7 that resembles 
that found in U2OS cells. Finally, the use of proteasome inhibitors rescued Mdm2- 
mediated degradation of E7, suggesting that the reduced expression of E7 in the 
presence of Mdm2 involves the proteasome. Overall, these results show that Mdm2 
enhances the proteasome-mediated degradation of E7, although whether this is 
ubiquitin-dependent or ubiquitin-independent is still to be determined. 
Immunofluorescence analyses, however, show that, in the presence of proteasome 
inhibitors, E7 localises with Mdm2 into nuclear structures that are enriched with 
ubiquitinated proteins. This may indicate that Mdm2 enhances ubiquitin- 
dependent proteasome degradation of E7 and is consistent with previous results 
showing that E7 is indeed poly-ubiquitinated in vivo (Oh et al, 2004a; W ang et al, 
2001). Furthermore, these nuclear structures co-localise with PM L bodies
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suggesting that the co-localisation of E7 to PML bodies (Bischof et al, £005) may 
mediate its degradation. This is also seen in CaSKi cells where, upon the inhibition 
of the proteasome, both E7 and PML appear to co-localise (Oh et al, 2004a). The 
destabilisation of E7 by Mdm2 may be an indirect consequence of its localisation to 
PML bodies where it acts to inhibit PML IV-induced senescence by disrupting 
pRB and p53/CBP activities (Bischof et al, 2005). This specific localisation of E7 to 
nuclear structures, which both mediates some of its functions and controls its 
activities, may be a mechanism by which E7 can be finely regulated.
Our results provide the first evidence that Mdm2 can mediate the degradation of a 
viral gene product. The expression of E7 was shown to induce p53 levels which 
results in an increased expression of Mdm2 (Thomas & Laimins, 1998). This may 
lead to a negative feedback loop whereby the cell can oppose increased levels of E7. 
However, the expression of E6 (which targets p53 for degradation) along with E7 
was shown to inhibit this increased expression of Mdm2 (Thomas & Laimins, 
1998). Therefore, the expression of full-length E6 protein, along with E7, during 
the viral life cycle may play an indirect role in inhibiting Mdm2-mediated 
degradation of E7. Interestingly, it was recently shown that pl9A RF (mouse 
homologue of Human pl4ARF) induces the relocalisation of E7 to the nucleolus 
and also inhibits some of E7’s activities (Pan et al, 2003). This is mediated through 
two sites on pl9A RF that are important for mediating the nucleolar localisation of 
Mdm2 (Weber et al, 2000). In their assays, Pan, et al, could not detect any binding 
between pl9ARF and E7. Therefore, the ARF protein-mediated localisation of 
Mdm2 to nucleoli may lead to the relocalisation of E7 as a result of E7’s binding to 
Mdm2. Our results however indicate that the activity of the ARF protein is 
dispensable for the localisation of Mdm2 (Bernardi et al, 2004), as well as E7, to the
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nucleolus, since Mdm2-E7 localisation at nucleoli is observed in U 20S cells which 
are mutated in pl4A RF expression.
Mdm2 is the second ubiquitin ligase identified that acts to destabilise E7. The SCF 
complex was previously shown to decrease the half-life of E7 and mediate its 
proteasome degradation (Oh et al, 2004a). E7 may be differentially targeted for 
degradation by either ubiquitin ligase complex depending on the stage of the cell 
cycle or the stimulation of certain pathways. The SCF complex targets multiple 
cell cycle regulatory proteins most of which are phosphorylated by CDKs before 
their degradation (Spruck & Strohmaier, 2002) indicating that the degradation of 
E7 by the SCF complex may depend on its phosphorylation status. The ability of 
E2 and CDK2 to increase the stability of E7 may occur through inhibiting the 
interaction of E7 with the SCF complex since we saw no rescue of Mdm2-mediated 
degradation of E7 upon increased expression of E2 or CDK2 (Figure 24). 
Therefore, the increase in E7 levels in G l/S-phase may be due to the inhibition of 
the SCF binding to CDK2-phosphorylated E7. Little is known about the regulation 
of Mdm2’s activities during the cell cycle in comparison to what is known about its 
stimuli-induced regulation (Meek & Knippschild, 2003). Almost 20% of the Mdm2 
protein sequence is composed of serine and threonine residues suggesting that 
phosphorylation plays an important role in regulating its activities. DNA damage- 
induced kinases such as DNA-activated protein kinase (DNA-PK) and ATM  were 
shown to phosphorylate Mdm2 and impede its ability to degrade p53 (Khosravi et 
al, 1999; Mayo et al, 1997). In this case, inhibiting Mdm2-mediated degradation of 
E7 may be important in order to circumvent restriction of cellular growth as a 
response to DNA damage. Furthermore the PI3-K/PKB pathway, which promotes 
cell proliferation stimulated by growth factors and cytokines, was also shown to
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increase the phosphorylation of Mdm2 and enhance its localisation to the nucleus 
(Mayo & Donner, 2001). Here, the ability of E7 to induce cellular proliferation can 
be substituted for by normal cellular pathways, and therefore its possible 
destabilisation by Mdm2 may be affordable for the virus.
Interaction between E2 and Mdm2
Several lines of evidence indicate a pro-apoptotic activity of E2 where taken out of 
the context of HPV gene expression. For example, papillomavirus E2 can induce 
apoptosis in a manner independent of other viral protein activities (Demeret et al, 
2003; W ebster et al, 2000) and the expression of the N-terminal half of E2 (lacking 
the DNA binding domain) results in growth inhibition of HPV-positive cell lines 
(Desaintes et al, 1999). In addition, full-length E2 stimulates p53 transcriptional 
activity in HPV-negative cell lines (Desaintes et al, 1997) and the expression of a 
dominant-negative p53 reduced apoptosis mediated by HPV-16 E2, but not HPV- 
18 E2 (Desaintes et al, 1997; W ebster et al, 2000). Here, we propose a novel 
mechanism by which HPV-16 E2 can regulate p53 activity by binding to Mdm2 
through its C-terminal domain, but an additional role of the N-terminal domain 
cannot be ruled out. W e detected a significant binding between Mdm2 and E2 both 
in vitro and in vivo. Although a similar region on the E2 protein mediates its 
interaction with p53 and Mdm2, we propose that the binding between E2 and 
Mdm2 is independent of E2’s binding to p53 for two reasons. First, E2 inhibits 
Mdm2-mediated degradation of pRB in a p53 negative background (Figure 28). 
Second, E2 and Mdm2 co-localise in SAOS-2 and M dm 2-/- p53-/- cells (Figure 
30c) in the presence of proteasome inhibitors. These structures resemble in their 
appearance and constitution nuclear stress bodies that form in the presence of
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cellular stress, such as the inhibition of the proteasome. Our results indicate that 
E2 can markedly inhibit Mdm2-mediated degradation of pRB and p53. In both 
cases, further investigation is required to show whether both proteins still retain 
their cellular activities in the presence of E2. In an HPV infection, the retention of 
p53 activity may be important at later stages of the life cycle at the upper epithelial 
layers. In this stage, the expression of Mdm2 and p53 may increase as a result of 
reduced E6 expression. E2 may therefore stimulate p53-mediated apoptosis to aid 
virion release by inhibiting Mdm2-mediated degradation of p53 (Blachon & 
Demeret, 2003).
We did not detect any change in the levels of E2 in the presence of Mdm2, but we 
observed that Mdm2 results in an increased transcriptional activation by E2. This 
is independent of pRB and p53 degradation by Mdm2 as this phenomenon is 
observed in both pRB/p53-positive and —negative cell lines. The role of the 
ubiquitin-proteasome machinery in transcription has been recently highlighted 
(Muratani & Tansey, 2003). One example of this is the regulation of c-myc 
transcriptional activities through its ubiquitination by the HectH9 ubiquitin-ligase 
(Adhikary et al, 2005). Ubiquitination of c-myc appears to be important for the 
recruitment of the p300 co-activator which is important for transcriptional 
activation of c-myc-regulated genes. In another case, the proteasome machinery 
was shown to affect oestrogen receptor a  (ERa) transcriptional activity (Reid et al,
2003). Here, the proteasome components were shown to bind to the promoter 
region and are important for the cycling of ERa on the transcription complex. 
Finally, in an HPV-related model, the activation of hTERT expression by HPV-16 
E6 was shown to be dependent on the interaction between E6 and E6AP, where 
both proteins were shown to bind interdependently to the hTER T gene promoter
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(Liu et al, 2005). In the case of Mdm2, its expression was shown to increase the 
transcriptional activity, by a poorly described mechanism, of a number of factors 
such as the p53 homolog p63 (Calabro et al, 2002) and ERa (Saji et al, 2001). Here, 
we show that Mdm2 can also increase the transcriptional activity of HPV-16 E2. 
Further investigation is required to identify whether Mdm2 is required to increase 
the ubiquitination of E2 by Mdm2, modulate the recruitment of cellular factors 
which may facilitate E2’s transcriptional activity or affect the binding of E2 to 
DNA. Furthermore, the localisation of E2 to PML bodies by Mdm2 may well aid 
the transcriptional activity of E2. Many transcription factors seem to congregate in 
nuclear structures such as PML bodies (Borden, 2002) which is thought to aid their 
activities. PML bodies were shown to enhance papillomavirus infectivity and 
transcription (Day et al, 2004) and this correlates with an increase in the efficiency 
of viral infection of a number of DNA tumour viruses (Everett, 2001). Mdm2 may 
increase viral gene expression from the late viral promoter resulting in an 
increased expression of the E4, L l  and L2  gene products and therefore facilitating 
virion production. Furthermore, localisation of E2 to PML bodies was shown 
previously to be mediated by L2 which is thought to enhance viral genome 
packaging (Day et al, 1998). Therefore, Mdm2 might also act to facilitate viral 
genome packaging by enhancing the localisation of E2, and in turn viral DNA, to 
PML bodies. Overall, these results indicate a novel cross-talk between the viral 
transcriptional activator and Mdm2 (Figure 33b).
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Materials and Methods
Cells and transfection. U 2OS (human osteosarcoma, p53+ /+  pRB+/+), SAOS-2 
(human osteosarcoma, p53-/- pRB-/-), Baby Rat Kidney (BRK), M dm 2-/- p53-/- 
mouse embryo fibroblasts (MEF), 293 (human embryonic kidney) and CaSKi 
(human cervical carcinoma, HPV16 positive) cells were grown in DMEM 
supplemented with 10% fetal bovine serum, penicillin-streptomyocin (lOOU/ml) 
and glutamine 292pg/ml. Transfection was carried out using calcium phosphate 
precipitation as described previously (Matlashewski et al, 1987) or using 
Lipofectamine2000 (Invitrogen) according the manufacturers protocol.
Plasmids.
E2: Expression plasmids encoding GST-tagged 16E2 were described previously 
including full-length GST-16E2 (Piccini et al, 1995) and N- and C-terminal halves 
(Massimi et al, 1999). C-terminal deletion mutants spanning residues 249-365 were 
amplified by PCR using the following primers: forward primer 5’
GACACCGGATCCCCCTGCCACACC; reverse primer 5'
GTTGTGAATTCAGTATCAAGATTTGTCATATA followed by digestion 
using BamHI and EcoRI restriction enzymes and cloning into pGEX-2T plasmid. 
16E2 in pcDNA was described previously (Bouvard et al, 1994a). GST-11E2 was 
generated by PCR amplification of a GFP-tagged HPV-11E2 construct (Merilyn 
Hibma) using the following primers: 5'-AGCGGATCCATGGAAGCAATA-3' (F), 
5'-AGCGAATTCTTACAATAAATGTAATGA-3' (R) and cloned into pG EX -2T 
plasmid using BamHI/EcoRI restriction sites. All Constructs were verified by
87
Materials and Methods
DNA sequencing. The N- and C- terminal halves of 16E2 used for in vitro 
translation-transcription were cloned into pSP64 plasmid as described previously 
(Piccini et al, 1995). For in vivo expression the following plasmids encoding 16E2 
were used CMV.16E2 (Bouvard et al, 1994a) and GFP-16E2 kindly provided by 
Ian Morgan.
E7: For bacterial expression of 16E7, plasmids encoding full-length GST-16E7 
(Massimi et al, 1996) and His-tagged 16E7 (Prathapam et al, 2001) were described 
previously. The N- and C-terminal halves of E7 were cloned into pGEX-2T using 
BamHI/EcoRI restriction sites by PCR amplification using the following primers, 
for the N-terminal half of 16E7: forward primer 5’
ACGTAGGGATCCCCAGCTGTAATC; reverse primer 5'
CTGGAATTCCAGCTGGACCATCTAT and for the C-terminal half of 16E7: 
forward primer 5’ CCAGGATCCCAAGCAGAACCGGAC; reverse primer 5’ 
CTCTTCCGAATTCGTACCTGCAGG. For in vitro translation transcription of 
E7 the following plasmids were used; pSP64.16E7 (Massimi et al, 1996); pSP64 
encoding the C-terminal mutants of 16E7 (Massimi et al, 1996) and 11E7 cloned 
into pcDNA from pJ4H plasmid (Storey et al, 1988) using EcoRI and H indlll 
restriction sites. For in vivo expression of 16E7 the following plasmids, described 
previously, were used; pj4Q.16E7 (Storey et al, 1988), CKII mutant of 16E7 
(pcDNA. 16E7 31/32) (Edmonds & Vousden, 1989) and N-terminally tagged HA- 
16E7 (Guccione et al, 2002). Untagged E7 was cloned into pcDNA from pJ4Q.E7 
using B am H l/H indlll restriction sites and the A3 and A4 mutants of E7 were 
cloned from pSP64 plasmid into pcDNA using EcoR l/Bam H l restriction sites. 
Subsequently, point mutants of E7 (including T5A, T57A, S71 and S71T57A) were
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mutated into alanine residues using site directed mutagenesis and verified using 
DNA sequencing.
Additional in  vitro  expression plasmids. For bacterial expression of GST-tagged 
proteins the following constructs were used; GST-16E1 (Storey et al, 1995); GST- 
TBP (Massimi et al, 1997).and GST-p53 (Massimi et al, 1999). For in vitro 
translation-transcription of Mdm2, a pSP65.Mdm2 was cloned by Miranda 
Thomas using EcoRI restriction sites.
Additional in  vivo  expression plasmids. The following plasmids used were 
previously described as follows; pG FP-N l (Clontech), pGFP-NLS (Clontech), 
Adenovirus E la  (Matlashewski et al, 1987), EJ-Ras (pEJ6.6) (Storey & Banks, 
1993), p6xE2BS-Luc reporter plasmid was kindly provided by Ian Morgan; 
CMV.pRB, pcDNA Pinl and G ST-Pinl were kindly provided by Giannino Del Sal, 
pcDNA3 HA PP2A Ca expressing the 35 kDa catalytic subunit of PP2A and PP2A 
dominant negative (DN) (Pirn et al, 2005), cyclin E and HA-tagged CDK2 
expression constructs were kindly provided by Ole Gjoerup, FLAG-p53 was kindly 
provided by Georgine Faulkner and Mdm2 pCoC expression plasmid was kindly 
provided by Karen Vousden.
Antibodies. Mouse monoclonal antibody against E2 (IF 1:100) and anti-E2 
polyclonal antibody (IF 1:200, WB 1:5000) have been described previously (Hibma 
et al, 1995; Massimi et al, 1999)
The following commercial antibodies were used at the dilutions indicated in 
brackets: anti-HA monoclonal antibody 12CA5 (Roche; WB 1:100, IF  1:100) anti- 
(3-galactosidase P-gal (Promega, WB 1:5000), polyclonal rabbit anti-oc-actin (Sigma
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1:1000), mouse anti-16E7 ED 17 (Santa-Cruz, also kindly provided by K. Monger, 
WB 1:100, IF 1:100) polyclonal rabbit anti-HA Y -ll (Santa-Cruz, IF 1:50), anti- 
PML rabbit polyclonal antibody (Santa Cruz, IF 1:100), anti-Daxx rabbit 
polyclonal antibody M-112 (Santa Cruz, IF 1:100), anti-Flag mouse monoclonal 
antibody M2 (Sigma, WB 1:1000, IF 1:1000), anti-Flag rabbit polyclonal antibody 
(Sigma, IF 1:1000), anti-GFP polyclonal antibody (Santa Cruz, WB 1:1000), mouse 
anti-p53 DO-1 (Santa Cruz, WB 1:1000, IF 1:100), goat anti-nucleolin C23 (Santa 
Cruz, IF 1:50), mouse anti-pRB (WB 1:500), mouse anti-y-tubulin (Sigma; WB 
1:5000, IF 1:200), mouse anti-conjugated ubiquitin FK2 (Biomol, lm g/m l stock, IF 
1:500), mouse anti-Mdm2 (Calbiochem, IF 1:30; also the mouse 2A10 antibody 
kindly provided by Giannino Del Sal, WB: 1:100).
Appropriate secondary antibodies conjugated to HRP were purchased from DAKO 
and used for W estern blotting at a dilution of 1:2000. In the case of 
immunofluorescence staining, secondary antibodies conjugated to either fluorescein 
or rhodamine were purchased from Molecular Probes and used at a concentration 
of 1:700.
BRK transformation assay. Primary Baby Rat Kidney (BRK) cells from 9-day-old 
W istar rats were transfected with either pJ4d:HPV-16E7 (6|lg), pcDNA 16E7 
(3|Ig) or Adenovirus E la  encoding plasmid (3 or 6 (Ig) along with 3(Xg EJ-Ras and 
3jig pcDNA encoding neomyocin resistance, with or without the indicated amounts 
of CMV.16E2 or GFP 16E2 expression plasmids. Cells were placed under selection 
in growth medium containing 200JIg/ml G418 for 2 weeks and then fixed, and
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colonies were stained with Giemsa-Blue (Diagnostica Merck) and then counted. 
The results obtained are representative of at least 3 independent experiments.
Fusion protein purification and in  vitro  binding assays. GST- and His-tagged 
fusion proteins were expressed and purified as described previously (Thomas et al,
1996). Briefly, 40ml of an overnight culture of E. coli strain DH5-a previously 
transformed with the appropriate expression plasmids were inoculated in a one to 
ten volume of Luria Broth (LB) containing ampicillin and grown at 37°C up to an 
OD of 0.6 at 395nm. Recombinant protein expression was induced for 3 hrs with 
lnM  isopropyl-(3-D-thiogalactopyranoside (IPTG, Sigma). The cells were 
harvested by centrifugation, disrupted by sonication in lysis buffer (PBS, 1% Triton 
X-100, 100 U /m l DNAse, protease inhibitors cocktail, Calbiochem) and the lysates 
were then cleared from cell debris by centrifugation. The GST-fusion proteins 
were then incubated for 1 hr with glutathione-conjugated agarose. In the case of 
Histidine protein purification, the following lysis buffer was used (lOmM Tris-HCl 
pH8.8, 300mM NaCl, 0.1 M phosphate buffer pH 8.0, lOOU/ml DNAse) and Ni- 
NTA (Qiagen Inc.) beads. His-fusion proteins were eluted with increasing amounts 
of imidazole. The purity of all fusion proteins was determined by SDS-PAGE and 
Coomassie Brilliant Blue R (Sigma) staining.
In vitro translation transcription was performed in rabbit reticulocyte lysate or 
wheat germ extract using the Promega T N T  system and were radiolabelled with 
£35S^cysteine (Amersham). Equal amounts of in wYro-translated proteins were 
added to GST fusion proteins bound to glutathione resin and incubated for 1 hr at 
4°C. After extensive washing with PBS containing 0.25% NP-40, or as otherwise 
indicated, the bound proteins were analysed by SDS-PAGE and autoradiography.
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Binding assays were quantified using Phosphor Imager and the percentage binding 
with respect to inputs was calculated.
GST pull downs from cellular extracts was performed by incubating GST-fusion 
proteins immobilised on resin with cell extract for 1 hr at 4°C on a rotating wheel. 
The resin was then washed extensively with the extraction buffer and bound 
proteins were detected using SDS-PAGE and W estern blot using the appropriate 
antibodies.
Direct binding assays were performed by incubating GST fusion proteins 
immobilised on resin with purified His-tagged 16E7 that had been eluted with 
imidazole containing buffer, for lh  at 4°C. After extensive washing the bound 
proteins were analysed by SDS-PAGE and W estern blotting using anti-16E7 
antibodies.
Im m unoprecipitation and W estern  b lotting . Total cellular extracts were 
prepared by directly lysing cells from 6-well dishes in SDS loading buffer. To 
obtain the soluble and insoluble cellular fractions separately, cells were lysed in 
either low-salt E l A buffer (25mM HEPES pH 7.0, 0.1%NP-40, 150mM NaCl, plus 
protease inhibitor cocktail I; Calbiochem) or high-salt E l A buffer containing 
500mM NaCl. After incubation on ice for 20 min lysates were cleared by 
centrifugation at 1300 rpm for lOmin. The supernatant (soluble fraction) and pellet 
(insoluble fraction) were analysed by SDS-PAGE and W estern blotting. For 
W estern blotting, 0.45 pm nitrocellulose membrane (Schleicher & Schuell) were 
used and membranes were blocked for 1 hr at 37°C in 10% milk followed by the 
incubation with the appropriate primary antibody diluted in 10% milk/0.5%Tween
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20 for 2 hrs. After several washings with PBS 0.5%Tween 20, secondary antibodies 
conjugated with HRP (Molecular Probes) were diluted in l%milk/o.5%Tween 20 
and incubated for 1 hr. Blots were developed using Amersham ECL technique 
according to the manufacturers instructions. In the case of W estern blotting of E7, 
0.22 pm membranes were used and membranes were treated with 0.5% 
glutaraldehyde in TBS for 0.5 hr at room temperature before blocking in 
l%milk/TBS for 1 hr at room temperature. Blots were then incubated with 
monoclonal anti-E7 antibodies (1:100) diluted in TBS l% m ilk/l% Tween 20 
overnight at 4°C. After incubation in appropriate 2° antibody, the blots were then 
developed using Femto solutions (Pierce) according to the manufacturer’s 
instructions.
For co-immunoprecipitation, U 2OS or 293 cells were transfected with the 
appropriate plasmids. 24 hrs later, E l A extraction was performed and the soluble 
fraction was incubated with anti-HA beads (Sigma) to pull down E7, or with anti- 
GFP antibodies to pull down GFP-E2 for 3-4 hrs on a rotating wheel at 4°C. In 
the case of GFP immunoprecipitation, Protein A agarose (Amersham) was added to 
the reaction 40 min prior to final washings. The agarose beads were extensively 
washed and precipitated proteins were analysed by W estern blotting using the 
antibodies indicated.
Half-life experiments. Lipofectamine2000 was used to transfect CaSKi cells with 
3pg of plasmid expressing E2 and M dm 2-/- p53-/- M EF cells with 1 jLLg pcDNA 
E7 with or without 2|Xg Mdm2 expression plasmid. 24 hrs after transfection, cells 
were treated for different time points as indicated with cycloheximide (50pg/ml in
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DMSO) to block protein synthesis. Total cellular extracts were then analysed by 
W estern blot and the intensity of the bands on the X-ray film was measured using 
Adobe Photoshop. The standard deviation was calculated from three independent 
assays.
RT-PCR. Total RNA was isolated from CaSKi cells (transfected as above) and 
BRK cells (transfected as in the transformation assay) 24 hrs after transfection 
using TRI Reagent (Sigma) according to the manufacturers instructions. A total of 
lpg  of RNA was subjected to reverse transcription (RT) using the RETROscript 
system (Ambion). No reverse transcriptase control was also added for assaying 
contamination with DNA. PCR was performed with 20 cycles and an annealing 
temperature of 55°C for E2, GFP and actin and 58°C for E7. PCR primers for 
actin, E7 (Yoshinouchi et al, 2003) and GFP (Grm et al, 2005) have been described 
previously. 16E2 primers were as follows: forward 5’
ATGGAGACTCTTTGCCAA; reverse 5’
TC ATAT AG AC ATA A AT CC AGTAG AC AC.
Immunofluorescence and Microscopy. Cells were stained and fixed for 
immunofluorescence as described previously (Grm et al, 2005). Briefly, cells were 
fixed with 3.7% paraformaldehyde in PBS for 20min and permeabilised with 0.1% 
Triton X-100 in PBS for 5min. Primary antibodies were incubated for 2 hr at 37°C, 
followed by extensive washing in PBS and incubation for 30 min at 37°C with 
secondary anti-rabbit or anti-mouse conjugated with fluorescein- or rhodamine 
(Molecular Probes). For the visualisation of chromosomes, cells were stained with
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1|JM Hoechst (Sigma No. 33258; bisBenzimide). Samples were then washed several 
times with water and mounted using Vectashield mounting medium (Vector 
Laboratories Inc.) on glass slides. The results obtained are representative of at 
least 3 independent experiments.
Slides were analysed using either a Leica DMLB fluorescence microscope equipped 
with a Leica photo camera (A01M871016) or a Zeiss LSM 510 confocal microscope 
and the data were collected utilising the XlOO objective oil immersion lens. To 
avoid cross talk between channels during confocal scanning the following settings 
were used: FITC was excited with a 488nm line of an Argon laser at which the 
excitation of rhodamine is negligible; rhodamine was excited with a 543nm line of a 
Neon laser at which the excitation of FITC is negligible. The FITC emission was 
monitored using a 505-530nm filter and the rhodamine was monitored using a 
560nm longpath filter.
Pre-perm eabilisation assay. U 20S cells were grown on coverslips in either 6 well 
dishes or in 6cm dishes and transfected with the plasmids indicated. 24 hrs after 
transfection, cells were washed with PBS and incubated for 7-min in 0.5% Triton 
X-100 in 20mM HEPES-KOH (pH 7.9), 50mM NaCl, 3mM MgCL and 300mM 
sucrose (Araujo et al, 2005). Cells were then processed for either 
immunofluorescence staining or W estern blotting (as described above).
Centrosom e abnorm ality assay. U 20S cells were grown on coverslips in 6well 
dishes. 24 hrs after transfection, cells were treated with nocodazole for a further 24 
hrs, and then fixed and processed for immunofluorescence (as described above).
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The following antibodies were used; monoclonal anti-y-tubulin to detect 
centrosomes, polyclonal anti-16E2 and polyclonal anti-HA to detect co-transfected 
HA-tagged E7.
Dual Luciferase reporter assay. U 2 OS and SAOS-2 cells were grown in 6 well 
dishes and transfected using calcium phosphate and Lipofectamine2000, 
respectively. Transfected plasmids include, 6xE2BS-Luc (1 pg), Renilla Luciferase 
(pRL) (0.0lpg) and a combination of GFP-16E2 (l.5pg), pcDNA E7 (as indicated) 
and Mdm2 (3pg). All transfections were repeated at least three times. Simultaneous 
expression of the pRL plasmid provided an internal control of baseline response 
and allowed for the normalisation of transfection efficiency. 24 hrs post 
transfection, cells were lysed and luciferase activity was measure using the Dual- 
luciferase assay kit as recommended by the manufacturer (Promega).
Cell cycle synchronisation. To synchronise U 2 OS cells, aphidicolin (Sigma) was 
added at a concentration of 4pg/m l to asynchronous growing cells for 24 hrs. The 
aphidicolin-containing medium was then removed and the cell culture was washed 
with 10ml of PBS. The PBS was then replaced with complete medium and the cell 
synchronization was checked by FACS analysis. Cells were harvested at different 
times (including time point 0 for G l phase) and DNA content was assessed by 
propidium iodide staining and FACS analysis as described previously (Banks et al., 
1990).
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In  vivo  degradation assays. U 20S (for FLAG-p53 degradation) and SAOS-2 (for 
pRB degradation) were transfected with 2)±g of FLAG-p53 or pRB expression 
plasmids, along with 0.15pg of LacZ or 3)dg of GFP-NLS expression plasmids as 
indicated. In addition, the following plasmids were also included; CMV.I6E 2 (3|dg), 
pcDNA E7 (4Jlg), Mdm2 (4|Xg). 24 hrs post-transfection, or as otherwise indicated, 
the cells were harvested and analysed by W estern blotting.
Inhibitors. The following inhibitors, summarised in Table 4, were dissolved in 
DMSO and used at the indicated concentrations: nocodazole (Sigma, 2pM), 
aphidicolin (Sigma, 5pM), okadaic acid (OA, Sigma, lOOnM), roscovitine 
(Calbiochem, 60pM), apigenin (Sigma, 30pM), CBZ (MG 132, Sigma, 50pM), LLnL 
(Sigma, 50pM), epoxymocin (Sigma, 25pM), Aurora kinas inhibitor II (Calbiochem, 
25pM), PIK3 inhibitor (Ly294002, Celbio). In addition, cells treated with DMSO 
alone were also included as a negative control.
Table 4: Description of the various inhibitors used.
Inhibitor Nocodazole aphidicolin Okadaicacid Roscovitine Apigenin
Inhibited
molecule Microtubule
DNA  
polymerase £ PP2A CDK1/C D K 2 CKII
Cone. 2|tM 5|iM lOOnM 60|iM 30 jiM
Company Sigma Sigma Sigma Calbiochem Sigma
Inhibitors cont.
Inhibitor Proteasome Aurora II inhibitor
PIK3
inhibitor Epoxomycin
Inhibited
molecule Auroral I PIK3 Proteasome
Cone. CBZ: 50|tM  
LLnL: 50JJ.M
2.5uM 25uM 25uM
Company Sigma Calbiochem Celbio Sigma
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In  vitro  phosphorylation. Purified GST fusion proteins were incubated with 
commercially purified CDK2 kinase (New England Biolabs) for 20 min at S0°C in 
phosphorylation buffer (20mM HEPES, pH 7.5, 20mM MgCl2, 0.3mM aprotinin, 1 
m M /Pepstatin) supplemented with 56nM £32P)]ATP (Amersham) and lOmM 
ATP. After extensive washing, the phosphorylated proteins were monitored by 
SDS-PAGE and autoradiography.
siRNA experim ents. U 20S cells seeded in 6cm dishes and transfected using 
Lipofectamine2000 (Invitrogen) with pcDNA 16E7 along with control siRNA 
against luciferase or siRNA against Mdm2 (siMdm2) (Dharmacon) according to 
the manufacturers procedure. 48 hrs after transfection, cells were harvested and 
protein levels assessed by W estern blot.
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